CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10719292,107192922,2,F,,20191212,20150119,20191218,EXP,,CA-ROCHE-1522743,ROCHE,,54,YR,,M,Y,,,20191218,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,107192922,OT,,,,,,,,,107192922,1,Bipolar disorder
11858629,118586299,9,F,,20191119,20151222,20191202,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2007-000002,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20191202,,CN,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Heart disease congenital,118586299,OT,,,118586299,1,20051201,20071211,,,118586299,1,Product used for unknown indication
11991033,119910338,8,F,,20191105,20160202,20191118,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004939,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20191118,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,119910338,OT,,,,,,,,,119910338,1,Product used for unknown indication
13081932,130819323,3,F,201612,20191030,20170103,20191101,EXP,,PHHY2014IN119925,NOVARTIS,,52,YR,,M,Y,,,20191101,,CN,IN,IN,EFAVIRENZ.,Death;Drug level decreased;Eye haemorrhage;Fall;Hand fracture;Osteoporosis;Therapy non-responder;Varicella,130819323,DE,,,,,,,,,130819323,1,Chronic myeloid leukaemia
13274205,1327420512,12,F,,20191106,20170227,20191117,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-016053,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20191117,,CN,FR,FR,EFAVIRENZ.,Abortion induced;Intentional product use issue;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,1327420512,OT,,,1327420512,1,201110,,,,1327420512,1,HIV infection
13274215,132742158,8,F,,20191022,20170227,20191025,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-015407,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20191025,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Intentional product use issue;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,132742158,OT,,,132742158,1,200909,,,,132742158,1,HIV infection
13278460,1327846010,10,F,,20191028,20170228,20191106,EXP,,FR-009507513-1702FRA008506,MERCK,"RUELLAN AL, VEYRAC G, BRUNET-CARTIER C, JARNET L, JOLLIET P.. ETONOGESTREL AND EFAVIRENZ DRUG INTERACTION: RISK OF CONTRACEPTION INEFFICACY. FUNDAMENTAL AND CLINICAL PHARMACOLOGY. 2016;30(SUPPL 1):50",32,YR,,F,Y,,,20191106,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,1327846010,OT,,,1327846010,1,201007,,,,1327846010,1,Contraception
13339761,133397618,8,F,,20191028,20170315,20191103,EXP,,FR-009507513-1702FRA008692,MERCK,"RUELLAN AL, VEYRAC G, BRUNET-CARTLER C, JARNET L, JOLLIET P. ETONOGESTREL AND EFAVIRENZ DRUG INTERACTION: RISK OF CONTRACEPTION INEFFICACY. FUNDAMENTAL AND CLINICAL PHARMACOLOGY. 2016;30 SUPPL (1):50",28,YR,,F,Y,,,20191103,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,133397618,OT,,,133397618,2,201206,,,,133397618,1,HIV infection
14248970,142489702,2,F,,20191210,20171204,20191224,EXP,IT-MINISAL02-436750,IT-MYLANLABS-2017M1075186,MYLAN,"TARTAGLIA A, FERRARA SM, SICA S, SANTANTONIO T.. SUCCESSFUL TREATMENT WITH TENOFOVIR ALAFENAMIDE OF A HIV/HEPATITIS B VIRUS COINFECTED PATIENT WITH HIV AND HEPATITIS B VIRUS DRUG RESISTANCE, END-STAGE RENAL DISEASE ON HAEMODIALYSIS.. AIDS. 2017;31(16):2314-2315",27,YR,,F,Y,,,20191224,,OT,IT,IT,EFAVIRENZ.,End stage renal disease;Pathogen resistance,142489702,OT,,,,,,,,,142489702,1,Antiretroviral therapy
14306973,143069736,6,F,,20191022,20171220,20191031,EXP,,CA-APOTEX-2017AP022582,APOTEX,,54,YR,,M,Y,,,20191031,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities,143069736,OT,,,,,,,,,143069736,1,Bipolar disorder
14307055,143070552,2,F,,20191031,20171220,20191112,EXP,,CA-APOTEX-2017AP022586,APOTEX,,,,,M,Y,,,20191112,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction,143070552,OT,,,,,,,,,143070552,1,Product used for unknown indication
14321297,143212972,2,F,20071111,20191101,20171223,20191112,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2010-000057,BRISTOL MYERS SQUIBB,,,,N,F,Y,,,20191112,,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Heart disease congenital,143212972,CA,,,143212972,1,20051201,20071211,,,143212972,1,Product used for unknown indication
14494652,144946527,7,F,,20190904,20180206,20191021,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-006996,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20191021,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,144946527,OT,,,,,,,,,144946527,1,HIV infection
14596238,145962387,7,F,,20191022,20180303,20191102,EXP,,FR-AUROBINDO-AUR-APL-2018-010672,AUROBINDO,,32,YR,,F,Y,,,20191102,,OT,US,FR,Efavirenz Film Coated Tablets,Abortion induced;Drug interaction;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue;Unwanted pregnancy,145962387,OT,,,145962387,1,20090901,,,,145962387,1,HIV infection
14652614,146526143,3,F,,20191204,20180319,20191211,EXP,,CA-APOTEX-2018AP007741,APOTEX,,44,YR,,M,Y,,,20191211,,CN,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,146526143,HO,,,,,,,,,146526143,1,Psychotic disorder
14713651,147136512,2,F,20171227,20191106,20180404,20191119,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2018012149,MACLEODS,,,,,,Y,,,20191119,,CN,US,ZA,EFAVIRENZ.,Chest pain;Electrocardiogram QT prolonged;Incorrect product administration duration,147136512,LT,,,147136512,1,20170330,20171227,,,147136512,1,Pulmonary tuberculosis
14961910,149619104,4,F,,20191104,20180601,20191115,EXP,,TZ-CIPLA (EU) LIMITED-2018TZ17784,CIPLA,,,,,,Y,,,20191115,,OT,TZ,TZ,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Immune reconstitution inflammatory syndrome;Tinea infection,149619104,OT,,,,,,,,,149619104,1,HIV infection WHO clinical stage II
14961911,149619112,2,F,,20191104,20180601,20191118,EXP,,TZ-CIPLA (EU) LIMITED-2018TZ17786,CIPLA,,,,,,Y,,,20191118,,OT,TZ,TZ,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Immune reconstitution inflammatory syndrome;Tinea infection,149619112,OT,,,,,,,,,149619112,1,HIV infection WHO clinical stage IV
15158165,151581658,8,F,20171006,20191211,20180718,20191225,EXP,,GB-AUROBINDO-AUR-APL-2018-036078,AUROBINDO,,43,YR,,F,Y,,,20191225,,CN,GB,GB,Efavirenz Film-coated Tablet,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,151581658,OT,,,151581658,1,20171006,20180205,,,151581658,1,HIV infection
15235019,152350196,6,F,20050813,20191111,20180803,20191114,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-002637",BOEHRINGER INGELHEIM,,,,N,,Y,,,20191114,,MD,FR,FR,EFAVIRENZ.,Anencephaly;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,152350196,CA,,,152350196,2,20050704,20050908,,,152350196,1,Foetal exposure during pregnancy
15243637,152436372,2,F,20060216,20191105,20180806,20191108,EXP,,FR-ABBVIE-18S-056-2442144-00,ABBVIE,,25,YR,,F,Y,,,20191108,,MD,FR,FR,SUSTIVA,Abortion induced;Exposure during pregnancy,152436372,CA,,,152436372,1,20050908,20050908,,,152436372,1,HIV infection
15249829,152498294,4,F,20060216,20191105,20180807,20191108,EXP,,FR-ABBVIE-18S-056-2444229-00,ABBVIE,,25,YR,,F,Y,,,20191108,,MD,FR,FR,SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,152498294,OT,,,152498294,1,20050908,20050908,,,152498294,1,HIV infection
15249841,152498413,3,F,,20191105,20180807,20191108,EXP,,FR-ABBVIE-18S-056-2442056-00,ABBVIE,,,,,F,Y,,,20191108,,MD,FR,FR,SUSTIVA,Arnold-Chiari malformation;Foetal exposure during pregnancy,152498413,OT,,,,,,,,,152498413,1,Maternal exposure timing unspecified
15357253,153572533,3,F,20060216,20191105,20180906,20191108,EXP,,FR-ABBVIE-18S-056-2474150-00,ABBVIE,,25,YR,,F,Y,,,20191108,,OT,FR,FR,SUSTIVA,Abortion induced;Exposure during pregnancy;Folate deficiency;Insomnia;Vertigo,153572533,OT,,,153572533,1,20050908,20050908,,,153572533,1,HIV infection
15363025,153630252,2,F,20171005,20191129,20180907,20191210,EXP,GB-EMA-DD-20180827-KSEVHUMANWT-125137,GB-NOVOPROD-619421,NOVO NORDISK,,,,,M,Y,,,20191210,,CN,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,153630252,OT,,,153630252,2,20171006,20180205,,,153630252,1,Product used for unknown indication
15530457,155304572,2,F,20180120,20191023,20181018,20191028,EXP,FR-AFSSAPS-TO20184140,FR-PFIZER INC-2018413828,PFIZER,,61,YR,,F,Y,,,20191028,,MD,FR,FR,SUSTIVA,Acute kidney injury;Renal tubular disorder,155304572,HO,,,155304572,1,20180117,20180214,,,155304572,1,Pelvic infection
15573679,155736797,7,F,,20191003,20181101,20191009,EXP,,CA-TEVA-2018-CA-968128,TEVA,,54,YR,,M,Y,,,20191009,,OT,CA,CA,SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities,155736797,OT,,,,,,,,,155736797,1,HIV infection
15612790,156127902,2,F,201808,20191210,20181113,20191223,EXP,,ET-JNJFOC-20181103945,JOHNSON AND JOHNSON,,36,YR,,M,Y,48,KG,20191223,,MD,ET,ET,EFAVIRENZ W/LAMIVUDINE/TENOFOVIR DISOPROXIL F,Dermatitis exfoliative,156127902,HO,,,156127902,1,20180816,20181031,,,156127902,1,Tuberculosis
15626751,156267517,7,F,,20191220,20181116,20191226,EXP,,CA-ABBVIE-18S-028-2552613-00,ABBVIE,,54,YR,,M,Y,,,20191226,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,156267517,OT,,,,,,,,,156267517,1,HIV infection
15630483,156304832,2,F,,20191002,20181119,20191014,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-104504,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20191014,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,156304832,OT,,,,,,,,,156304832,1,HIV infection
15923667,159236673,3,F,20051019,20190930,20190206,20191007,EXP,,FR-AUROBINDO-AUR-APL-2019-006030,AUROBINDO,,36,YR,,F,Y,82,KG,20191007,,CN,FR,FR,SUSTIVA,Abdominal pain;Chills;Diarrhoea;Eyelid oedema;Lip oedema;Pyrexia;Rash;Thrombocytopenia,159236673,HO,,,159236673,1,20051201,20051202,,,159236673,1,Pyrexia
15934528,159345285,5,F,,20191118,20190207,20191120,EXP,,FR-MYLANLABS-2019M1011151,MYLAN,,,,N,F,Y,,,20191120,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,159345285,CA,,,159345285,1,20050523,20050908,,,159345285,1,HIV infection
15950518,159505185,5,F,2014,20190930,20190211,20191003,EXP,ES-EMA-20180731-AUTODUP-27044000,ES-MYLANLABS-2019M1011377,MYLAN,"BRAVO I, ALVAREZ H, MARINO A, CLOTET B, MOLTO J.. RECURRENT CORONARY DISEASE IN HIV-INFECTED PATIENTS: ROLE OF DRUG?DRUG INTERACTIONS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2018;84 (7):1617-9",39,YR,,M,Y,,,20191003,,MD,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,159505185,HO,,,159505185,1,2012,,,,159505185,1,HIV infection
16020890,160208909,9,F,,20191214,20190301,20191227,EXP,,CA-AUROBINDO-AUR-APL-2019-010743,AUROBINDO,,54,YR,,M,Y,,,20191227,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,160208909,OT,,,,,,,,,160208909,1,HIV infection
16037652,160376525,5,F,2008,20191217,20190305,20191225,EXP,,US-ASTRAZENECA-2018SF65040,ASTRAZENECA,,35,YR,,M,Y,90.3,KG,20191225,,,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;End stage renal disease;Hyperparathyroidism secondary;Nephrogenic anaemia;Nephropathy;Renal failure;Renal injury,160376525,HO,,,160376525,1,201201,201712,,,160376525,1,Gastrooesophageal reflux disease
16051353,160513534,4,F,20110825,20191130,20190308,20191211,EXP,,FR-AUROBINDO-AUR-APL-2018-062564,AUROBINDO,,35,YR,,F,Y,,,20191211,,OT,FR,FR,Efavirenz Film Coated Tablets,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160513534,OT,,,,,,,,,160513534,1,HIV infection
16064738,160647385,5,F,20171006,20191220,20190312,20191227,EXP,,GB-MYLANLABS-2019M1022917,MYLAN,,43,YR,,F,Y,,,20191227,,MD,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,160647385,OT,,,160647385,1,20171006,20180205,,,160647385,1,HIV infection
16064851,160648515,5,F,2017,20191219,20190312,20191227,EXP,,US-ABBVIE-19K-163-2698768-00,ABBVIE,,71,YR,,M,Y,73.09,KG,20191226,,CN,US,US,SUSTIVA,Axillary mass;Axillary pain;Cataract;Decreased appetite;Erectile dysfunction;Infection;Mobility decreased;Neoplasm;Neoplasm skin;Pain;Psoriasis;Psoriatic arthropathy;Rhinitis;Skin discolouration;Subcutaneous abscess;Weight increased;Wound secretion,160648515,OT,,,160648515,1,20150504,201901,,,160648515,1,Psoriatic arthropathy
16081150,160811504,4,F,,20191007,20190316,20191016,EXP,,CA-AUROBINDO-AUR-APL-2019-013361,AUROBINDO,,54,YR,,M,Y,,,20191016,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,160811504,OT,,,,,,,,,160811504,1,HIV infection
16081152,160811523,3,F,,20191201,20190316,20191211,EXP,,CA-AUROBINDO-AUR-APL-2019-013775,AUROBINDO,,,,,M,Y,,,20191212,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,160811523,HO,,,,,,,,,160811523,1,Product used for unknown indication
16170692,161706922,2,F,,20191219,20190408,20191227,EXP,,AT-MYLANLABS-2019M1031449,MYLAN,"TAYLOR N, TOUZEAU V, GEIT M, GISINGER M, EGLE A, GREIL R, ET AL... RALTEGRAVIR IN PREGNANCY: A CASE SERIES PRESENTATION.. INTERNATIONAL JOURNAL OF STD + AIDS.. 2011;22(6):350-60",39,YR,,F,Y,,,20191227,,OT,AT,AT,EFAVIRENZ.,Acute stress disorder;Drug abuse;Exposure during pregnancy;Premature rupture of membranes;Rebound effect;Viral load increased,161706922,OT,,,,,,,,,161706922,1,Antiretroviral therapy
16183901,161839012,2,F,,20191021,20190411,20191028,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-015928",BOEHRINGER INGELHEIM,,52,YR,,M,Y,,,20191028,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,161839012,OT,,,,,,,,,161839012,1,HIV infection
16206633,162066332,2,F,,20191003,20190417,20191010,EXP,,CA-AUROBINDO-AUR-APL-2019-019815,AUROBINDO,,,,,M,Y,,,20191011,,OT,CA,CA,EFAVIRENZ.,Depression;Drug interaction,162066332,OT,,,,,,,,,162066332,1,Product used for unknown indication
16251297,162512975,5,F,20050813,20191112,20190429,20191118,EXP,,FR-GILEAD-2019-0404516,GILEAD,,,,N,,Y,,,20191118,,CN,FR,FR,EFAVIRENZ.,Anencephaly;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,162512975,OT,,,162512975,1,20050813,20050908,,,162512975,1,HIV infection
16261847,162618476,6,F,,20191202,20190501,20191213,EXP,,CA-GILEAD-2019-0405133,GILEAD,,,,I,,Y,,,20191213,,OT,CA,CA,EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162618476,OT,,,,,,,,,162618476,1,HIV infection
16271062,162710626,6,F,,20191111,20190503,20191111,EXP,,FR-ABBVIE-19S-056-2763487-00,ABBVIE,,,,N,,Y,,,20191111,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,162710626,CA,,,162710626,1,20050908,20050908,,,162710626,1,Maternal exposure timing unspecified
16284485,162844855,5,F,,20190910,20190508,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-025238,AUROBINDO,,,,I,,Y,,,20191120,,OT,CA,CA,Tenofovir + efavirenz + emtricitabine,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162844855,OT,,,,,,,,,162844855,1,HIV infection
16288958,162889583,3,F,20050813,20191105,20190509,20191116,EXP,,FR-AUROBINDO-AUR-APL-2019-026163,AUROBINDO,,25,YR,,F,Y,,,20191116,,CN,FR,FR,EFAVIRENZ.,Abortion induced;Exposure during pregnancy;Folate deficiency;Insomnia;Vertigo,162889583,OT,,,162889583,1,20050513,20050908,,,162889583,1,HIV infection
16297818,162978185,5,F,20060216,20191111,20190510,20191111,EXP,,FR-ABBVIE-09P-056-0558368-00,ABBVIE,,,,,F,Y,,,20191111,,MD,FR,FR,SUSTIVA,Anencephaly;Brain herniation;Encephalocele;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,162978185,OT,,,162978185,1,20050908,,,,162978185,1,Maternal exposure timing unspecified
16302622,163026222,2,F,,20191113,20190513,20191126,EXP,,GB-CIPLA LTD.-2019GB02975,CIPLA,,,,,,Y,,,20191126,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,163026222,OT,,,163026222,2,20171006,,,,163026222,1,HIV infection
16303467,163034674,4,F,,20191113,20190513,20191118,EXP,,GB-HETERO-HET2019GB00641,HETERO,,43,YR,,F,Y,,,20191119,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,163034674,OT,,,163034674,1,20171006,,,,163034674,1,HIV infection
16308155,163081552,2,F,,20191118,20190514,20191202,EXP,,CA-ALVOGEN-2019-ALVOGEN-099727,ALVOGEN,,,,N,,Y,,,20191202,,OT,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,163081552,OT,,,,,,,,,163081552,1,Product used for unknown indication
16308301,163083012,2,F,20060216,20191105,20190514,20191108,EXP,,FR-ABBVIE-19S-056-2772098-00,ABBVIE,,25,YR,,F,Y,,,20191108,,MD,FR,FR,EFAVIRENZ.,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,163083012,OT,,,163083012,1,20050908,20050908,,,163083012,1,HIV infection
16340539,163405393,3,F,,20190917,20190522,20191001,EXP,,CA-AUROBINDO-AUR-APL-2019-027542,AUROBINDO,,44,YR,,M,Y,,,20191001,,OT,CA,CA,SUSTIVA,Anxiety,163405393,OT,,,,,,,,,163405393,1,Psychotic disorder
16346235,163462353,3,F,,20191124,20190523,20191205,EXP,,CA-AUROBINDO-AUR-APL-2019-027597,AUROBINDO,,54,YR,,M,Y,,,20191205,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,163462353,OT,,,,,,,,,163462353,1,HIV infection
16470787,164707872,2,F,,20191118,20190624,20191122,EXP,,UG-MYLANLABS-2019M1058214,MYLAN,,20,YR,,F,Y,,,20191122,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Exposure during pregnancy;Foetal death,164707872,OT,,,164707872,1,20141022,,,,164707872,1,HIV infection
16470789,164707895,5,F,,20191007,20190624,20191011,EXP,,UG-MYLANLABS-2019M1058216,MYLAN,,,,,F,Y,3.7,KG,20191011,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Congenital skin dimples;Congenital umbilical hernia;Foetal exposure during pregnancy,164707895,CA,,,164707895,1,20170721,,,,164707895,1,HIV infection
16474440,164744404,4,F,20151123,20191001,20190625,20191009,EXP,,BR-GILEAD-2019-0414876,GILEAD,,26,YR,A,F,Y,,,20191009,,MD,BR,BR,EFAVIRENZ.,Hepatitis fulminant,164744404,OT,,,164744404,1,20150831,20160107,,,164744404,1,HIV infection
16528627,165286273,3,F,,20191003,20190703,20191014,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2019AMR119230,VIIV,,35,YR,,M,Y,,,20191014,,MD,BR,BR,EFAVIRENZ.,Blood creatine phosphokinase increased;Cardiovascular disorder;Chest pain;Electrocardiogram ST segment elevation;Myocarditis;Troponin I increased,165286273,OT,,,,,,,,,165286273,1,HIV infection
16528645,165286453,3,F,,20191003,20190703,20191014,EXP,,BR-GLAXOSMITHKLINE-BR2019AMR119230,GLAXOSMITHKLINE,,35,YR,,M,Y,,,20191014,,MD,BR,BR,EFAVIRENZ.,Blood creatine phosphokinase increased;Cardiovascular disorder;Chest pain;Electrocardiogram ST segment elevation;Myocarditis;Troponin I increased,165286453,OT,,,,,,,,,165286453,1,HIV infection
16536587,165365874,4,F,20050813,20191107,20190706,20191120,EXP,,FR-AUROBINDO-AUR-APL-2019-038824,AUROBINDO,,,,N,,Y,,,20191120,,CN,FR,FR,EFAVIRENZ.,Anencephaly;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,165365874,OT,,,165365874,1,20050704,20050908,,,165365874,1,HIV infection
16542961,165429612,2,F,,20191201,20190709,20191211,EXP,,CA-AUROBINDO-AUR-APL-2019-037761,AUROBINDO,,54,YR,,M,Y,,,20191211,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,165429612,OT,,,,,,,,,165429612,1,Product used for unknown indication
16543052,165430522,2,F,,20191201,20190709,20191211,EXP,,CA-AUROBINDO-AUR-APL-2019-037770,AUROBINDO,,,,,M,Y,,,20191211,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,165430522,OT,,,,,,,,,165430522,1,Product used for unknown indication
16544746,165447465,5,F,2019,20191009,20190709,20191018,EXP,,ZA-JNJFOC-20190630148,JOHNSON AND JOHNSON,,29,YR,,M,Y,62,KG,20191018,,MD,ZA,ZA,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Cor pulmonale acute;Drug-induced liver injury;Hyponatraemia;Pneumothorax;Respiratory distress;Seizure,165447465,HO,,,165447465,1,20190311,20190528,,,165447465,1,Tuberculosis
16549468,165494682,2,F,,20191124,20190710,20191205,EXP,,CA-AUROBINDO-AUR-APL-2019-037814,AUROBINDO,,54,YR,,M,Y,,,20191205,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,165494682,OT,,,,,,,,,165494682,1,Product used for unknown indication
16582236,165822362,2,F,,20191010,20190717,20191017,EXP,,CA-AUROBINDO-AUR-APL-2019-039430,AUROBINDO,,,,,,Y,,,20191017,,OT,CA,CA,Mylan efavirenz/emtricitabine/tenofovir disoproxil fumarate,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,165822362,OT,,,,,,,,,165822362,1,HIV infection
16590194,165901944,4,F,,20191118,20190718,20191125,EXP,,CA-TEVA-2018-CA-968075,TEVA,,44,YR,,M,Y,,,20191125,,OT,CA,CA,SUSTIVA,Anxiety,165901944,HO,,,,,,,,,165901944,1,HIV infection
16638680,166386804,4,F,,20191009,20190726,20191015,EXP,,UG-MYLANLABS-2019M1069122,MYLAN,,,,,F,Y,,,20191015,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,166386804,CA,,,166386804,1,20140818,20190524,,,166386804,1,HIV infection
16647133,166471332,2,F,20190501,20191028,20190730,20191031,EXP,GB-MHRA-EYC 00203835,GB-GILEAD-2019-0420758,GILEAD,,47,YR,A,F,Y,,,20191031,,PH,GB,GB,EFAVIRENZ/EMTRICITABIN/TENOFOVIR DISOPROXIL MYLAN,Diarrhoea;Product substitution issue,166471332,DS,,,166471332,1,20190401,,,,166471332,1,HIV infection
16662141,166621416,6,F,2012,20191114,20190802,20191120,EXP,,PHHY2019AT170861,NOVARTIS,SCHALK WH. DUAL ART IN THE MANAGEMENT OF ADVERSE EVENTS. JATROS INFEKTIOLOGIE + GASTROENTEROLOGIE. 2019;22,69,YR,,M,Y,90,KG,20191120,,OT,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166621416,OT,,,166621416,1,20031107,20040423,,,166621416,1,Antiretroviral therapy
16663673,166636734,4,F,2012,20191125,20190802,20191209,EXP,,AT-JNJFOC-20190735116,JOHNSON AND JOHNSON,SCHALK H. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019;22:.,69,YR,,M,Y,90,KG,20191209,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166636734,OT,,,166636734,1,20111107,20120419,,,166636734,1,Antiviral treatment
16667632,166676322,2,F,,20190726,20190805,20191212,EXP,,BW-GILEAD-2019-0421543,GILEAD,,,,N,,Y,,,20191212,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital hydrocephalus;Foetal exposure during pregnancy,166676322,OT,,,,,,,,,166676322,1,HIV infection
16667679,166676792,2,F,,20190726,20190805,20191212,EXP,,BW-GILEAD-2019-0421975,GILEAD,,,,N,,Y,,,20191212,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital hydrocephalus;Foetal exposure during pregnancy,166676792,OT,,,,,,,,,166676792,1,HIV infection
16667778,166677782,2,F,,20190726,20190805,20191212,EXP,,BW-GILEAD-2019-0421978,GILEAD,,,,N,,Y,,,20191212,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital hydrocephalus;Foetal exposure during pregnancy,166677782,CA,,,,,,,,,166677782,1,HIV infection
16667780,166677802,2,F,,20190726,20190805,20191212,EXP,,BW-GILEAD-2019-0421976,GILEAD,,,,N,,Y,,,20191212,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital hydrocephalus;Foetal exposure during pregnancy,166677802,CA,,,,,,,,,166677802,1,HIV infection
16667782,166677822,2,F,,20190726,20190805,20191212,EXP,,BW-GILEAD-2019-0421977,GILEAD,,,,N,,Y,,,20191212,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital hydrocephalus;Foetal exposure during pregnancy,166677822,CA,,,,,,,,,166677822,1,HIV infection
16671350,166713503,3,F,2012,20191121,20190806,20191204,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-073480,BRISTOL MYERS SQUIBB,SCHALK WH. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019;2:22,69,YR,,M,Y,90,KG,20191204,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166713503,OT,,,166713503,1,20040423,20140606,,,166713503,1,Antiretroviral therapy
16734269,167342695,5,F,,20191118,20190823,20191129,EXP,,CA-AUROBINDO-AUR-APL-2019-054545,AUROBINDO,,54,YR,,M,Y,,,20191129,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,167342695,OT,,,,,,,,,167342695,1,Bipolar disorder
16737441,167374412,2,F,,20191002,20190823,20191004,EXP,,TH-GILEAD-2019-0424899,GILEAD,"LIEGEON G, HARRISON L, NECHBA A, HALUE G, BANCHONGKIT S, NILMANAT A, YUTTHAKASEMSUNT N, PATHIPVANICH P, THONGPAEN S, LERTKOONALAK R, ALTHAUS T, LALLEMANT M, MARY JY, JOURDAIN G. LONG TERM RENAL FUNCTION IN ASIAN HIV-1 INFECTED ADULTS RECEIVING TENOFOVIR DISOPROXIL FUMARATE WITHOUT PROTEASE INHIBITORS. J. INFECT.. 2019;UNK:UNK. DOI:10.1016/J.JINF.2019.08.006",36,YR,A,M,Y,53,KG,20191004,,MD,TH,TH,EFAVIRENZ.,Death,167374412,DE,,,,,,,,,167374412,1,HIV infection
16737448,167374482,2,F,,20191002,20190823,20191004,EXP,,TH-GILEAD-2019-0424305,GILEAD,"LIEGEON G, HARRISON L, NECHBA A, HALUE G, BANCHONGKIT S, NILMANAT A, YUTTHAKASEMSUNT N, PATHIPVANICH P, THONGPAEN S, LERTKOONALAK R, ALTHAUS T, LALLEMANT M, MARY JY, JOURDAIN G. LONG TERM RENAL FUNCTION IN ASIAN HIV-1 INFECTED ADULTS RECEIVING TENOFOVIR DISOPROXIL FUMARATE WITHOUT PROTEASE INHIBITORS. J. INFECT.. 2019;UNK:UNK. DOI:10.1016/J.JINF.2019.08.006",44,YR,A,M,Y,52,KG,20191004,,MD,TH,TH,EFAVIRENZ.,Death,167374482,DE,,,,,,,,,167374482,1,HIV infection
16737882,167378823,3,F,,20191002,20190824,20191017,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-004747,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20191017,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,167378823,OT,,,,,,,,,167378823,1,HIV infection
16741532,167415322,2,F,,20191216,20190826,20191231,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-080379,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20191231,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,167415322,CA,,,,,,,,,167415322,1,HIV infection
16768439,167684393,3,F,201004,20191031,20190903,20191106,EXP,,LT-MYLANLABS-2019M1081910,MYLAN,,49,YR,,M,Y,,,20191106,,MD,LT,LT,EFAVIRENZ.,Diarrhoea;Drug resistance;Extrapulmonary tuberculosis;Hypoaesthesia;Immune reconstitution inflammatory syndrome;Lymph node tuberculosis;Myalgia;Pancreatitis;Viraemia,167684393,OT,,,167684393,1,20100324,201110,,,167684393,1,Product used for unknown indication
16785413,167854133,3,F,,20191218,20190909,20191231,EXP,,AT-ROCHE-2394721,ROCHE,"TAYLOR N, TOUZEAU V, GEIT M, GISINGER M, EGLE A, GREIL R ET AL. RALTEGRAVIR IN PREGNANCY: A CASE SERIES PRESENTATION.. INTERNATIONAL JOURNAL OF STD AND AIDS. 2011;22(6):358-360.",39,YR,,F,Y,,,20191231,,OT,AT,AT,EFAVIRENZ.,Acute stress disorder;Maternal exposure during pregnancy;Premature rupture of membranes;Rebound effect;Viral load increased,167854133,HO,,,,,,,,,167854133,1,HIV infection
16803928,168039282,2,F,20190717,20191009,20190913,20191011,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019022900,MACLEODS,,,,,,Y,,,20191011,,CN,US,BR,LAMIVUDINE+ EFAVIRENZ + TENOFOVIR,Abortion spontaneous;Maternal exposure during pregnancy,168039282,OT,,,168039282,1,20170927,,,,168039282,1,HIV infection
16806887,168068873,3,F,,20191002,20190913,20191015,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-088376,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20191015,,OT,GB,GB,EFAVIRENZ.,Drug interaction;Embolism venous,168068873,OT,,,,,,,,,168068873,1,HIV infection
16806891,168068912,2,F,2001,20191211,20190913,20191223,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-086812,BRISTOL MYERS SQUIBB,,38,YR,,M,Y,,,20191223,,OT,ES,ES,EFAVIRENZ.,Neurotoxicity,168068912,OT,,,168068912,1,2001,2001,,,168068912,1,HIV infection
16824274,168242745,5,F,20060216,20191213,20190918,20191220,EXP,,FR-MYLANLABS-2019M1087495,MYLAN,,,,N,,Y,,,20191220,,CN,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,168242745,OT,,,168242745,1,20050704,20050908,,,168242745,1,HIV infection
16830668,168306683,3,F,,20191009,20190920,20191022,EXP,,AT-ROCHE-1061841,ROCHE,"TAYLOR N, TOUZEAU V, GEIT M, GISINGER M, EGLE A, GREIL R ET AL. RALTEGRAVIR IN PREGNANCY A CASE SERIES PRESENTATION. INTERNATIONAL JOURNAL OF STD ANSD AIDS 2011;22 (6):358-360.",39,YR,,F,Y,,,20191023,,MD,AT,AT,EFAVIRENZ.,Acute stress disorder;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes;Rebound effect;Viral load increased,168306683,HO,,,,,,,,,168306683,1,Antiretroviral therapy
16832095,168320954,4,F,,20191126,20190920,20191210,EXP,,ES-AUROBINDO-AUR-APL-2019-060571,AUROBINDO,,,,A,,Y,,,20191210,,OT,ES,ES,EFAVIRENZ.,Disseminated tuberculosis;Drug interaction;Hepatotoxicity;Neurotoxicity,168320954,OT,,,168320954,1,2008,,,,168320954,1,HIV infection
16846318,168463182,2,F,,20191202,20190924,20191205,EXP,,FR-MYLANLABS-2019M1089332,MYLAN,,,,N,,Y,,,20191205,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,168463182,DE,,,168463182,1,20050523,20050908,,,168463182,1,Product used for unknown indication
16846790,168467902,2,F,,20191104,20190924,20191105,EXP,,FR-MYLANLABS-2019M1088803,MYLAN,,,,N,,Y,,,20191105,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Encephalocele;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,168467902,OT,,,168467902,2,20050704,20050908,,,168467902,1,Product used for unknown indication
16854144,168541442,2,F,,20191003,20190926,20191011,EXP,,GB-AUROBINDO-AUR-APL-2019-062196,AUROBINDO,,,,A,M,Y,,,20191011,,OT,GB,GB,EFAVIRENZ.,Drug interaction;Embolism venous,168541442,OT,,,,,,,,,168541442,1,Embolism venous
16859830,168598302,2,F,,20191002,20190927,20191015,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-092601,BRISTOL MYERS SQUIBB,,,,,M,Y,3.23,KG,20191015,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,168598302,CA,,,168598302,1,20070403,20070510,,,168598302,1,Product used for unknown indication
16860477,168604772,2,F,200809,20191104,20190927,20191107,EXP,,ES-MYLANLABS-2019M1089643,MYLAN,,68,YR,,M,Y,69.5,KG,20191107,,MD,ES,ES,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN;EFAVIRENZ.",Pulmonary tuberculosis,168604772,OT,,,168604772,1,200805,200905,,,168604772,1,HIV infection
16863601,168636012,2,F,20190806,20191017,20190927,20191023,EXP,GB-MHRA-EYC 00208628,GB-MYLANLABS-2019M1090380,MYLAN,,69,YR,,M,Y,,,20191023,,PH,GB,GB,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Abdominal pain upper;Diarrhoea;Product substitution issue,168636012,DS,,,168636012,1,20190806,20190821,,,168636012,1,HIV infection
16867501,168675012,2,F,20190301,20191017,20190930,20191022,EXP,GB-MHRA-EYC 00208612,GB-MYLANLABS-2019M1090169,MYLAN,,47,YR,,M,Y,,,20191022,,PH,GB,GB,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Abdominal distension;Depression;Diarrhoea;Product substitution issue;Suicidal ideation,168675012,DS,,,168675012,1,20190301,20190501,,,168675012,1,HIV infection
16874037,168740371,1,I,,20190919,20191001,20191001,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-092106,BRISTOL MYERS SQUIBB,,43,YR,,,Y,,,20191001,,OT,CH,CH,EFAVIRENZ.,Drug dependence;Weight decreased,168740371,OT,,,168740371,1,201405,201412,,,168740371,1,Antiretroviral therapy
16889040,168890402,2,F,,20190927,20191007,20191011,EXP,,IN-CIPLA LTD.-2019IN06677,CIPLA,,,,,,Y,,,20191011,,OT,IN,IN,EFAVIRENZ.,Foetal exposure during pregnancy;Human immunodeficiency virus transmission,168890402,OT,,,,,,,,,168890402,1,Prophylaxis against HIV infection
16889041,168890412,2,F,,20190927,20191007,20191011,EXP,,IN-CIPLA LTD.-2019IN06678,CIPLA,,,,,,Y,,,20191011,,OT,IN,IN,EFAVIRENZ.,Exposure during pregnancy;Human immunodeficiency virus transmission,168890412,OT,,,,,,,,,168890412,1,HIV infection
16889107,168891072,2,F,,20190927,20191007,20191011,EXP,,IN-CIPLA (EU) LIMITED-2019IN06675,CIPLA,,,,,,Y,,,20191011,,OT,IN,IN,EFAVIRENZ.,Exposure during pregnancy;Human immunodeficiency virus transmission,168891072,OT,,,,,,,,,168891072,1,HIV test positive
16889463,168894631,1,I,,20190923,20191007,20191007,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-096878,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20191007,,OT,IN,IN,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,168894631,OT,,,,,,,,,168894631,1,HIV infection
16889473,168894731,1,I,,20190923,20191007,20191007,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-094422,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20191007,,OT,IN,IN,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,168894731,OT,,,,,,,,,168894731,1,HIV infection
16889486,168894861,1,I,,20190923,20191007,20191007,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-096879,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20191007,,OT,IN,IN,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,168894861,OT,,,,,,,,,168894861,1,HIV infection
16890420,168904201,1,I,,20190926,20191007,20191007,EXP,,LS-JNJFOC-20190937016,JOHNSON AND JOHNSON,,21,YR,,F,Y,40,KG,20191007,,MD,LS,LS,EFAVIRENZ.,Pelvic inflammatory disease;Transaminases increased,168904201,OT,,,168904201,1,20180907,20190225,,,168904201,1,Tuberculosis
16891038,168910381,1,I,20190501,20190919,20191007,20191007,EXP,,GB-MYLANLABS-2019M1088608,MYLAN,,47,YR,,F,Y,,,20191007,,PH,GB,GB,EFAVIRENZ/EMTRICITABIN/TENOFOVIRDISOPROXIL MYLAN,Diarrhoea;Product substitution issue,168910381,DS,,,,,,,,,168910381,1,Product used for unknown indication
16891046,168910461,1,I,201012,20190930,20191007,20191007,EXP,,PT-MYLANLABS-2019M1091846,MYLAN,,,,A,F,Y,,,20191007,,MD,PT,PT,EFAVIRENZ.,Drug ineffective;Maternal exposure during pregnancy;Treatment noncompliance;Viral load increased,168910461,OT,,,168910461,1,201006,201006,,,168910461,1,HIV infection
16895338,168953381,1,I,20180303,20191001,20191008,20191008,EXP,,GB-MYLANLABS-2019M1092758,MYLAN,,31,YR,,F,Y,,,20191008,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,168953381,OT,,,,,,,,,168953381,1,HIV infection
16895391,168953911,1,I,2012,20191001,20191008,20191008,EXP,,"AT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-12-105155",BOEHRINGER INGELHEIM,SCHALK H. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019,69,YR,,M,Y,90,KG,20191008,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,168953911,OT,,,168953911,1,20120419,20121203,,,168953911,1,Antiretroviral therapy
16895713,168957131,1,I,,20190930,20191008,20191008,EXP,,CA-PFIZER INC-2019429513,PFIZER,,,,,,Y,,,20191008,,OT,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,168957131,OT,,,,,,,,,168957131,1,Diffuse large B-cell lymphoma
16896724,168967241,1,I,200311,20190123,20191008,20191008,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-007833,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,82,KG,20191008,,CN,FR,FR,SUSTIVA,Abdominal pain;Chills;Diarrhoea;Eyelid oedema;Lip oedema;Pyrexia;Rash;Thrombocytopenia,168967241,OT,,,168967241,1,20051201,20051202,,,168967241,1,Pyrexia
16897571,168975711,1,I,,20191003,20191009,20191009,EXP,,CA-TEVA-2019-CA-1119046,TEVA,,54,YR,,M,Y,,,20191009,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,168975711,OT,,,,,,,,,168975711,1,Product used for unknown indication
16897772,168977723,3,F,,20190927,20191009,20191011,EXP,,IN-CIPLA LTD.-2019IN06679,CIPLA,,,,,,Y,,,20191011,,OT,IN,IN,EFAVIRENZ.,Exposure via breast milk;Foetal exposure during pregnancy;Human immunodeficiency virus transmission,168977723,OT,,,,,,,,,168977723,1,Prophylaxis against HIV infection
16898099,168980996,6,F,,20191130,20191009,20191211,EXP,,PT-AUROBINDO-AUR-APL-2019-064780,AUROBINDO,,45,YR,,M,Y,,,20191211,,OT,PT,PT,Efavirenz Film Coated Tablets,Alopecia;Breast pain;Diabetes insipidus;Erectile dysfunction;Gynaecomastia;Hypogonadism;Hypopituitarism;Libido decreased;Polydipsia;Weight increased,168980996,OT,,,168980996,1,2010,,,,168980996,1,HIV infection
16902940,169029401,1,I,,20190903,20191010,20191010,EXP,,BR-MYLANLABS-2019M1094721,MYLAN,,37,YR,,F,Y,,,20191010,,OT,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Maternal exposure during pregnancy,169029401,OT,,,169029401,1,20170927,,,,169029401,1,HIV infection
16904475,169044751,1,I,20170101,,20190819,20190819,DIR,,,FDA-CTU,,54,YR,,M,N,,,20190819,N,PH,US,US,EFAVIRENZ TAB 600MG,Hepatic steatosis,,,169044751,HP,169044751,1,2010,,,,,,
16906076,169060761,1,I,,20190610,20191010,20191010,EXP,,CA-AUROBINDO-AUR-APL-2019-034286,AUROBINDO,,54,YR,,M,Y,,,20191011,,OT,CA,CA,EFAVIRENZ.,Drug ineffective;Hypertriglyceridaemia,169060761,OT,,,,,,,,,169060761,1,HIV infection
16906252,169062522,2,F,,20191011,20191011,20191024,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-095044,BRISTOL MYERS SQUIBB,,52,YR,,F,Y,,,20191024,,OT,US,US,SUSTIVA,No adverse event,,,,,,,,,,,169062522,1,Antiretroviral therapy
16907243,169072431,1,I,,20191002,20191011,20191011,EXP,,DE-VIIV HEALTHCARE LIMITED-NG2019GSK183006,VIIV,,7,YR,,M,Y,,,20191011,,OT,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169072431,OT,,,,,,,,,169072431,1,HIV infection
16907244,169072441,1,I,,20191002,20191011,20191011,EXP,,DE-VIIV HEALTHCARE LIMITED-NG2019GSK183008,VIIV,,42,YR,,M,Y,,,20191011,,OT,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169072441,OT,,,,,,,,,169072441,1,HIV infection
16907247,169072471,1,I,,20191002,20191011,20191011,EXP,,DE-GLAXOSMITHKLINE-NG2019GSK183006,GLAXOSMITHKLINE,,7,YR,,M,Y,,,20191011,,OT,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169072471,OT,,,,,,,,,169072471,1,HIV infection
16907249,169072491,1,I,,20191002,20191011,20191011,EXP,,DE-GLAXOSMITHKLINE-NG2019GSK183008,GLAXOSMITHKLINE,,42,YR,,M,Y,,,20191011,,OT,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169072491,OT,,,,,,,,,169072491,1,HIV infection
16908146,169081461,1,I,20190929,20191007,20191011,20191011,EXP,,US-GILEAD-2019-0432211,GILEAD,,60,YR,A,M,Y,99.7,KG,20191011,,CN,US,US,SUSTIVA,Abnormal dreams;Atrial fibrillation;Burn oral cavity;Burning sensation;Emotional disorder;Feeling hot;Flushing;Genital burning sensation;Genital rash;Gingival bleeding;Hypertension;Mental disorder;Myocardial infarction;Nervous system disorder;Nightmare;Oral disorder;Poisoning;Poor dental condition;Skin burning sensation,169081461,OT,,,169081461,2,201901,,,,169081461,1,HIV test positive
16909478,169094781,1,I,,20191003,20191011,20191011,EXP,,CA-TEVA-2019-CA-1118732,TEVA,,,,,M,Y,,,20191011,,OT,CA,CA,EFAVIRENZ.,Depression;Drug interaction,169094781,OT,,,,,,,,,169094781,1,Product used for unknown indication
16912943,169129431,1,I,,20191003,20191014,20191014,EXP,,CA-TEVA-2019-CA-1118733,TEVA,,,,,M,Y,,,20191014,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,169129431,OT,,,,,,,,,169129431,1,Product used for unknown indication
16914788,169147883,3,F,,20191115,20191014,20191128,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-095326,BRISTOL MYERS SQUIBB,,45,YR,,M,Y,,,20191128,,MD,PT,PT,EFAVIRENZ.,Alopecia;Breast pain;Diabetes insipidus;Erectile dysfunction;Gynaecomastia;Hypogonadism;Hypopituitarism;Libido decreased;Polydipsia;Weight increased,169147883,HO,,,169147883,1,2010,,,,169147883,1,HIV infection
16920425,169204251,1,I,,20191002,20191015,20191015,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-096179,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20191015,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,169204251,OT,,,,,,,,,169204251,1,Product used for unknown indication
16927028,169270281,1,I,20190727,20191010,20191016,20191016,EXP,,GB-MYLANLABS-2019M1096983,MYLAN,,,,A,M,Y,,,20191016,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial fibrillation,169270281,OT,,,,,,,,,169270281,1,Product used for unknown indication
16928470,169284701,1,I,,20191007,20191017,20191017,EXP,,ZA-CIPLA LTD.-2019ZA06872,CIPLA,"ROSSOUW TM, VAN DYK G, VAN ZYL G. RAPID EMERGENCE OF RESISTANCE TO ANTIRETROVIRAL TREATMENT AFTER UNDISCLOSED PRIOR EXPOSURE: A CASE REPORT. SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE. 2019;20 (1):1 TO 3",,,,,Y,,,20191017,,OT,ZA,ZA,EFAVIRENZ.,Drug resistance;Gene mutation,169284701,OT,,,169284701,1,20140806,,,,169284701,1,HIV infection
16929724,169297241,1,I,,20191003,20191017,20191017,EXP,,BR-MACLEODS PHARMACEUTICALS US LTD-MAC2019023376,MACLEODS,,,,,,Y,,,20191017,,OT,BR,BR,EFAVIRENZ.,Toxic epidermal necrolysis;Treatment failure,169297241,OT,,,169297241,1,2012,,,,169297241,1,Acquired immunodeficiency syndrome
16931549,169315491,1,I,20191015,20191015,20191017,20191017,EXP,,US-GILEAD-2019-0433322,GILEAD,,43,YR,A,F,Y,,,20191017,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Unevaluable event,169315491,HO,,,169315491,1,201803,,,,169315491,1,HIV infection
16932704,169327042,2,F,,20191007,20191018,20191023,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-099269,BRISTOL MYERS SQUIBB,,,,,,Y,,,20191023,,MD,GB,GB,EFAVIRENZ.,Adverse event,169327042,OT,,,,,,,,,169327042,1,Product used for unknown indication
16934410,169344101,1,I,201909,20191014,20191018,20191018,EXP,,NVSC2019BR005027,NOVARTIS,,62,YR,,F,Y,,,20191018,,CN,BR,BR,EFAVIRENZ.,Dizziness;Intraocular pressure decreased;Malaise;Pruritus;Transplant rejection;Vision blurred,169344101,OT,,,169344101,1,2006,,,,169344101,1,Product used for unknown indication
16934559,169345591,1,I,,20160210,20191018,20191018,EXP,,US-009507513-1602KEN006228,MERCK,,,,,F,Y,,,20191018,,OT,KE,KE,EFAVIRENZ.,Pregnancy with implant contraceptive;Unintended pregnancy,169345591,OT,,,,,,,,,169345591,1,Contraception
16934617,169346171,1,I,,20191004,20191018,20191018,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019023328,MACLEODS,,,,,,Y,,,20191018,,OT,US,US,EFAVIRENZ.,Acute kidney injury,169346171,OT,,,,,,,,,169346171,1,HIV infection
16935237,169352371,1,I,20171006,20191011,20191018,20191018,EXP,,GB-MYLANLABS-2019M1097788,MYLAN,,,,A,F,Y,,,20191018,,MD,GB,GB,EFAVIRENZ.,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,169352371,OT,,,169352371,2,20171006,20180205,,,169352371,1,Product used for unknown indication
16937381,169373811,1,I,,20191015,20191018,20191018,EXP,,CA-TEVA-2019-CA-1124072,TEVA,,52,YR,,M,Y,,,20191018,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,169373811,OT,,,,,,,,,169373811,1,HIV infection
16938068,169380681,1,I,,20191015,20191018,20191018,EXP,,CA-TEVA-2019-CA-1123923,TEVA,,45,YR,,M,Y,,,20191018,,OT,CA,CA,EFAVIRENZ.,Bone pain;Hypophosphataemia;Musculoskeletal deformity;Osteomalacia;Renal tubular dysfunction,169380681,DS,,,,,,,,,169380681,1,HIV infection
16939274,169392741,1,I,,20191011,20191021,20191021,EXP,,NG-AUROBINDO-AUR-APL-2019-067617,AUROBINDO,,7,YR,,M,Y,,,20191021,,OT,DE,DE,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169392741,OT,,,,,,,,,169392741,1,HIV infection
16939571,169395711,1,I,,20191015,20191021,20191021,EXP,,CA-TEVA-2019-CA-1123890,TEVA,,61,YR,,M,Y,,,20191021,,PH,CA,CA,EFAVIRENZ.,Hip fracture;Osteopenia;Osteoporosis;Spinal compression fracture,169395711,HO,,,,,,,,,169395711,1,HIV infection
16939753,169397531,1,I,,20191011,20191021,20191021,EXP,,DE-AUROBINDO-AUR-APL-2019-067618,AUROBINDO,,42,YR,,M,Y,,,20191021,,OT,NG,DE,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169397531,OT,,,,,,,,,169397531,1,HIV infection
16941938,169419381,1,I,2005,20191009,20191021,20191021,EXP,,US-VIIV HEALTHCARE LIMITED-US2019GSK184821,VIIV,,,,A,M,Y,,,20191021,,OT,US,US,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169419381,OT,,,,,,,,,169419381,1,HIV infection
16941939,169419391,1,I,2005,20191009,20191021,20191021,EXP,,US-GLAXOSMITHKLINE-US2019GSK184821,GLAXOSMITHKLINE,,,,A,M,Y,,,20191021,,OT,US,US,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,169419391,OT,,,,,,,,,169419391,1,HIV infection
16941947,169419471,1,I,20190620,20190923,20191021,20191021,EXP,GB-MHRA-EYC 00207191,GB-MYLANLABS-2019M1090161,MYLAN,,33,YR,,M,Y,,,20191021,,PH,GB,GB,Efavirenz/Emtricitabin/Tenofovirdisoproxil Mylan,Diarrhoea;Product substitution issue,169419471,DS,,,169419471,1,20190620,20190808,,,169419471,1,HIV infection
16944576,169445761,1,I,,20191015,20191022,20191022,EXP,,CA-TEVA-2019-CA-1123953,TEVA,,52,YR,,M,Y,,,20191022,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,169445761,OT,,,,,,,,,169445761,1,HIV infection
16944950,169449501,1,I,,20191014,20191022,20191022,EXP,,NG-MYLANLABS-2019M1100090,MYLAN,"OGAR CK, ABIOLA A, YUAH D, IBRAHIM A, OREAGBA IA, AMADI EC, ET AL. A RETROSPECTIVE REVIEW OF SERIOUS ADVERSE DRUG REACTION REPORTS IN THE NIGERIAN VIGIFLOW DATABASE FROM SEPTEMBER 2004 TO DECEMBER 2016. PHARM-MED 2019;33(2):145-157.",,,,,Y,,,20191022,,OT,NG,NG,EFAVIRENZ.,Confusional state;Hyperkinesia;Somnolence;Stridor,169449501,DE,,,,,,,,,169449501,1,Product used for unknown indication
16944951,169449511,1,I,,20191014,20191022,20191022,EXP,,NG-MYLANLABS-2019M1100093,MYLAN,"OGAR CK, ABIOLA A, YUAH D, IBRAHIM A, OREAGBA IA, AMADI EC, ET AL. A RETROSPECTIVE REVIEW OF SERIOUS ADVERSE DRUG REACTION REPORTS IN THE NIGERIAN VIGIFLOW DATABASE FROM SEPTEMBER 2004 TO DECEMBER 2016. PHARM-MED 2019;33(2):145-157.",,,,,Y,,,20191022,,OT,NG,NG,EFAVIRENZ.,Confusional state;Oedema;Somnolence,169449511,DE,,,,,,,,,169449511,1,Product used for unknown indication
16945297,169452971,1,I,,20191015,20191022,20191022,EXP,,GB-MYLANLABS-2019M1098658,MYLAN,"OLIVEIRA R, PATEL RK, TAYLOR C, CZUPRYNSKA J, ARYA R, ROBERTS LN. DIRECT ORAL ANTICOAGULANTS FOR THE MANAGEMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH HIV ? A SINGLE CENTRE EXPERIENCE.. BRITISH JOURNAL OF HAEMATOLOGY. 2019;186:5:E148-E151",,,A,M,Y,,,20191022,,OT,GB,GB,EFAVIRENZ.,Drug interaction;Embolism venous,169452971,OT,,,,,,,,,169452971,1,Product used for unknown indication
16947165,169471651,1,I,,20191014,20191022,20191022,EXP,,NG-MYLANLABS-2019M1100095,MYLAN,"OGAR CK, ABIOLA A, YUAH D, IBRAHIM A, OREAGBA IA, AMADI EC, ET AL. A RETROSPECTIVE REVIEW OF SERIOUS ADVERSE DRUG REACTION REPORTS IN THE NIGERIAN VIGIFLOW DATABASE FROM SEPTEMBER 2004 TO DECEMBER 2016. PHARM-MED 2019;33(2):145-157.",,,,,Y,,,20191022,,OT,NG,NG,EFAVIRENZ.,Pyrexia;Rash,169471651,DE,,,,,,,,,169471651,1,Product used for unknown indication
16947309,169473091,1,I,,20191014,20191022,20191022,EXP,,NG-MYLANLABS-2019M1100109,MYLAN,"OGAR CK, ABIOLA A, YUAH D, IBRAHIM A, OREAGBA IA, AMADI EC, ET AL. A RETROSPECTIVE REVIEW OF SERIOUS ADVERSE DRUG REACTION REPORTS IN THE NIGERIAN VIGIFLOW DATABASE FROM SEPTEMBER 2004 TO DECEMBER 2016. PHARM-MED 2019;33(2):145-157.",,,,,Y,,,20191022,,OT,NG,NG,EFAVIRENZ.,Confusional state;Dizziness,169473091,DE,,,,,,,,,169473091,1,Product used for unknown indication
16958349,169583492,2,F,,20191030,20191024,20191107,EXP,,ZA-GLAXOSMITHKLINE-ZA2019GSK191886,GLAXOSMITHKLINE,"MEHTA UC, VAN SCHALKWYK C, NAIDOO P, RAMKISSOON A, MHLONGO O, MAHARAJ NR ET AL.. BIRTH OUTCOMES FOLLOWING ANTIRETROVIRAL EXPOSURE DURING PREGNANCY: INITIAL RESULTS FROM A PREGNANCY EXPOSURE REGISTRY IN SOUTH AFRICA. SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE. 2019;20 (1):A971, DOI:10.4102/SAJHIVMED.V2",,,,,Y,,,20191107,,MD,ZA,ZA,SUSTIVA,Brachydactyly;Foetal exposure during pregnancy,169583492,OT,,,,,,,,,169583492,1,HIV infection
16958483,169584832,2,F,,20191030,20191024,20191107,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2019GSK191886,VIIV,"MEHTA UC, VAN SCHALKWYK C, NAIDOO P, RAMKISSOON A, MHLONGO O, MAHARAJ NR ET AL.. BIRTH OUTCOMES FOLLOWING ANTIRETROVIRAL EXPOSURE DURING PREGNANCY: INITIAL RESULTS FROM A PREGNANCY EXPOSURE REGISTRY IN SOUTH AFRICA. SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE. 2019;20 (1):A971, DOI:10.4102/SAJHIVMED.V2",,,,,Y,,,20191107,,MD,ZA,ZA,SUSTIVA,Brachydactyly;Foetal exposure during pregnancy,169584832,CA,,,,,,,,,169584832,1,HIV infection
16960763,169607631,1,I,,20191018,20191025,20191025,EXP,,CA-TEVA-2019-CA-1126754,TEVA,,,,,M,Y,,,20191025,,OT,CA,CA,EFAVIRENZ.,Congenital eyelid malformation;Congenital nose malformation;Deafness bilateral;Dysmorphism;Eyelid ptosis congenital;Hypertelorism of orbit;Maternal exposure during pregnancy;Radioulnar synostosis;Skull malformation;Synostosis,169607631,CA,,,,,,,,,169607631,1,Vulvovaginal candidiasis
16960846,169608461,1,I,,20191017,20191025,20191025,EXP,,ZA-GILEAD-2019-0434475,GILEAD,"MEHTA UC, VAN SCHALKWYK C, NAIDOO P, RAMKISSOON A, MHLONGO O, MAHARAJ NR, NAIDOO N, FIEGGEN K, URBAN MF, KROG S, WELTE A, DHEDA M, PILLAY Y, MORAN NF. BIRTH OUTCOMES FOLLOWING ANTIRETROVIRAL EXPOSURE DURING PREGNANCY: INITIAL RESULTS FROM A PREGNANCY EXPOSURE REGISTRY IN SOUTH AFRICA. SOUTH AFR J HIV MED. 2019;20(1):971-982. DOI:10.4102/SAJHIVMED.V20I1.971",,,N,,Y,3.1,KG,20191025,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Meningomyelocele,169608461,OT,,,,,,,,,169608461,1,HIV infection
16960853,169608532,2,F,,20191105,20191025,20191106,EXP,,ZA-GILEAD-2019-0434473,GILEAD,,,,N,,Y,,,20191106,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Low set ears;Talipes,169608532,CA,,,,,,,,,169608532,1,HIV infection
16961106,169611062,2,F,,20191105,20191025,20191107,EXP,,ZA-GILEAD-2019-0434476,GILEAD,,,,N,,Y,,,20191107,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cleft lip and palate;Foetal exposure during pregnancy,169611062,OT,,,,,,,,,169611062,1,HIV infection
16961170,169611701,1,I,,20191017,20191025,20191025,EXP,,ZA-GILEAD-2019-0434477,GILEAD,"MEHTA UC, VAN SCHALKWYK C, NAIDOO P, RAMKISSOON A, MHLONGO O, MAHARAJ NR, NAIDOO N, FIEGGEN K, URBAN MF, KROG S, WELTE A, DHEDA M, PILLAY Y, MORAN NF. BIRTH OUTCOMES FOLLOWING ANTIRETROVIRAL EXPOSURE DURING PREGNANCY: INITIAL RESULTS FROM A PREGNANCY EXPOSURE REGISTRY IN SOUTH AFRICA. SOUTH AFR J HIV MED. 2019;20(1):971-982. DOI:10.4102/SAJHIVMED.V20I1.971",,,N,,Y,,,20191025,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dysmorphism;Foetal exposure during pregnancy;Micrognathia;Polydactyly,169611701,CA,,,,,,,,,169611701,1,HIV infection
16961241,169612412,2,F,,20191105,20191025,20191107,EXP,,ZA-GILEAD-2019-0434478,GILEAD,,,,N,,Y,,,20191107,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Exomphalos;Foetal exposure during pregnancy,169612412,OT,,,,,,,,,169612412,1,HIV infection
16961463,169614632,2,F,,20191104,20191025,20191106,EXP,,ZA-GILEAD-2019-0434479,GILEAD,,,,N,,Y,,,20191106,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hypospadias,169614632,CA,,,,,,,,,169614632,1,HIV infection
16962586,169625861,1,I,,20191015,20191025,20191025,EXP,,ZA-JNJFOC-20191021784,JOHNSON AND JOHNSON,,51,YR,,F,Y,,,20191025,,MD,ZA,ZA,EFAVIRENZ.,Gastrointestinal haemorrhage,169625861,HO,,,169625861,1,20190620,2019,,,169625861,1,Pulmonary tuberculosis
16962914,169629141,1,I,,20191013,20191025,20191025,EXP,,US-CMP PHARMA-2019CMP00028,CMP PHARMA,"GUPTA A, MONTEPIEDRA G, AARON L, ET AL.. ISONIAZID PREVENTIVE THERAPY IN HIV-INFECTED PREGNANT AND POSTPARTUM WOMEN.. N ENGL J MED.. 2019;381(14):1333-1346",,,A,F,Y,,,20191025,,MD,US,US,EFAVIRENZ.,Drug interaction;Exposure during pregnancy;Hepatic failure,169629141,OT,,,,,,,,,169629141,1,HIV infection
16962915,169629151,1,I,,20191013,20191025,20191025,EXP,,US-CMP PHARMA-2019CMP00029,CMP PHARMA,"GUPTA A, MONTEPIEDRA G, AARON L, ET AL. ISONIAZID PREVENTIVE THERAPY IN HIV-INFECTED PREGNANT AND POSTPARTUM WOMEN. N ENGL J MED. 2019;381(14):1333-1346",,,A,F,Y,,,20191025,,OT,US,US,EFAVIRENZ.,Drug interaction;Hepatic failure,169629151,DE,,,,,,,,,169629151,1,HIV infection
16962939,169629391,1,I,,20191017,20191025,20191025,EXP,,ZA-GILEAD-2019-0434474,GILEAD,"MEHTA UC, VAN SCHALKWYK C, NAIDOO P, RAMKISSOON A, MHLONGO O, MAHARAJ NR, NAIDOO N, FIEGGEN K, URBAN MF, KROG S, WELTE A, DHEDA M, PILLAY Y, MORAN NF. BIRTH OUTCOMES FOLLOWING ANTIRETROVIRAL EXPOSURE DURING PREGNANCY: INITIAL RESULTS FROM A PREGNANCY EXPOSURE REGISTRY IN SOUTH AFRICA. SOUTH AFR J HIV MED. 2019;20(1):971-982. DOI:10.4102/SAJHIVMED.V20I1.971",,,N,,Y,,,20191025,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Meningomyelocele,169629391,OT,,,,,,,,,169629391,1,HIV infection
16965651,169656511,1,I,20190909,,20190909,20190909,DIR,,,FDA-CTU,,53,YR,,M,N,,,20190909,N,CN,US,US,EFAVIRENZ TAB 600MG,Therapy cessation,,,,,169656511,1,199909,,,,,,
16967344,169673441,1,I,,20191021,20191028,20191028,EXP,,IT-MYLANLABS-2019M1101321,MYLAN,,,,,F,Y,,,20191028,,OT,IT,IT,EFAVIRENZ.,Drug interaction;Virologic failure,169673441,OT,,,,,,,,,169673441,1,HIV infection
16970634,169706342,2,F,,20191029,20191029,20191101,EXP,,US-GILEAD-2019-0435047,GILEAD,,58,YR,A,M,Y,,,20191101,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Depression;Suicidal ideation,169706342,OT,,,169706342,1,2009,2015,,,169706342,1,HIV infection
16975294,169752941,1,I,20190501,20191025,20191030,20191030,EXP,GB-EMA-DD-20191023-KHARE_I-123904,GB-MYLANLABS-2019M1102559,MYLAN,,47,YR,,F,Y,,,20191030,,PH,GB,GB,Efavirenz/Emtricitabin/Tenofovirdisoproxil Mylan,Diarrhoea;Product substitution issue,169752941,DS,,,,,,,,,169752941,1,HIV infection
16978172,169781721,1,I,,20191029,20191031,20191031,EXP,,US-GILEAD-2019-0435343,GILEAD,,,,E,M,Y,,,20191031,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal disorder,169781721,HO,,,,,,,,,169781721,1,HIV infection
16979900,169799001,1,I,,20191022,20191031,20191031,EXP,,NVSC2019MW019751,NOVARTIS,,,,A,,Y,,,20191031,,OT,MW,MW,EFAVIRENZ.,Electrocardiogram QT prolonged;Product use in unapproved indication,169799001,OT,,,,,,,,,169799001,1,HIV infection
16989675,169896751,1,I,,20191029,20191104,20191104,EXP,,ZA-GILEAD-2019-0435459,GILEAD,,,,I,,Y,,,20191104,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hypospadias,169896751,OT,,,,,,,,,169896751,1,HIV infection
16991019,169910193,3,F,,20191104,20191104,20191113,EXP,,ZA-GILEAD-2019-0435933,GILEAD,,,,N,,Y,,,20191113,,OT,ZA,ZA,EFAVIRENZ.,Brachydactyly;Foetal exposure during pregnancy,169910193,CA,,,,,,,,,169910193,1,HIV infection
16992764,169927641,1,I,,,20190923,20190923,DIR,,,FDA-CTU,,,,,M,N,,,20190907,N,OT,US,US,EFAVIRENZ 600MG,Coordination abnormal,,,169927641,HP,169927641,1,20030711,,,,169927641,1,HIV infection
16998200,169982003,3,F,,20191111,20191106,20191114,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2019200075,VIIV,,,,N,,Y,,,20191114,,OT,ZA,ZA,EFAVIRENZ.,Brachydactyly;Foetal exposure during pregnancy,169982003,CA,,,,,,,,,169982003,1,HIV infection
16998253,169982533,3,F,,20191111,20191106,20191114,EXP,,ZA-GLAXOSMITHKLINE-ZA2019200075,GLAXOSMITHKLINE,,,,N,,Y,,,20191114,,OT,ZA,ZA,EFAVIRENZ.,Brachydactyly;Foetal exposure during pregnancy,169982533,CA,,,,,,,,,169982533,1,HIV infection
16998903,169989031,1,I,,20191022,20191106,20191106,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2019-09089,ALKEM,"GUPTA A, MONTEPIEDRA G, AARON L, THERON G, ET AL.. ISONIAZID PREVENTIVE THERAPY IN HIV-INFECTED PREGNANT AND POSTPARTUM WOMEN. THE NEW ENGLAND JOURNAL OF MEDICINE.. 2019;381(14):1333-1346",36,YR,,F,Y,,,20191106,,OT,US,US,TENOFOVIR/LAMUVIDINE/EFAVIRENZ,Drug interaction;Hepatitis fulminant,169989031,OT,,,,,,,,,169989031,1,Antibiotic prophylaxis
16998905,169989051,1,I,,20191022,20191106,20191106,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2019-09088,ALKEM,"GUPTA A, MONTEPIEDRA G, AARON L, THERON G, ET AL.. ISONIAZID PREVENTIVE THERAPY IN HIV-INFECTED PREGNANT AND POSTPARTUM WOMEN. THE NEW ENGLAND JOURNAL OF MEDICINE.. 2019;381(14):1333-1346",34,YR,,F,Y,,,20191106,,OT,US,US,TENOFOVIR/LAMUVIDINE/EFAVIRENZ,Drug interaction;Hepatitis fulminant;Neutropenia,169989051,DE,,,,,,,,,169989051,1,Antibiotic prophylaxis
17000237,170002371,1,I,,20191029,20191106,20191106,EXP,,NVSC2019ZA023705,NOVARTIS,,,,N,,Y,,,20191106,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL 600 MG/200 MG/245 MG FILM,Meningomyelocele,170002371,DE,,,,,,,,,170002371,1,Foetal exposure during pregnancy
17004531,170045311,1,I,20190827,20191105,20191107,20191107,EXP,GB-MHRA-EYC 00210716,GB-VIIV HEALTHCARE LIMITED-GB2019200750,VIIV,,55,YR,,M,Y,76,KG,20191107,,MD,GB,GB,EFAVIRENZ.,Myocardial infarction,170045311,HO,,,170045311,1,20080201,20191014,,,170045311,1,HIV infection
17005802,170058021,1,I,,20191106,20191107,20191107,EXP,,IT-GILEAD-2019-0436557,GILEAD,,51,YR,A,M,Y,,,20191107,,CN,IT,IT,SUSTIVA,Osteoporosis,170058021,OT,,,,,,,,,170058021,1,HIV infection
17012614,170126141,1,I,,20191104,20191109,20191109,EXP,,US-ROCHE-2467410,ROCHE,"SHALLIS R, GLEESON S, AZAR M, MALINIS M, XU M, SEROPIAN S, GOWDA L, AND ZEIDAN A ALLOGENEIC STEM CELL TRANSPLANTATION AND COMBINATION ANTIRETROVIRAL THERAPY: CAUTIONS, COMPLICATIONS, AND CONSIDERATIONS. LEUKEMIA AND LYMPHOMA 2019 AUG 24;60(10):2584-7.",49,YR,,F,Y,,,20191109,,OT,US,US,EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE,Myelodysplastic syndrome;Pneumonia haemophilus;Streptococcal bacteraemia;Thrombocytopenia,170126141,OT,,,,,,,,,170126141,1,B-cell lymphoma
17018774,170187742,2,F,,20191108,20191112,20191122,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-105665,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20191122,,OT,ZA,ZA,EFAVIRENZ.,Brachydactyly;Foetal exposure during pregnancy,170187742,CA,,,,,,,,,170187742,1,Product used for unknown indication
17021355,170213551,1,I,201310,20191104,20191112,20191112,EXP,,GB-MYLANLABS-2019M1107742,MYLAN,,39,YR,,M,Y,,,20191112,,OT,GB,GB,EFAVIRENZ.,Acute myeloid leukaemia,170213551,HO,,,170213551,1,200308,200311,,,170213551,1,B precursor type acute leukaemia
17023002,170230021,1,I,,20191029,20191112,20191112,EXP,,"ZA-LANNETT COMPANY, INC.-ZA-2019LAN001122",LANNETT,,,,,,Y,,,20191112,,OT,ZA,ZA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPRO,Foetal exposure during pregnancy;Meningomyelocele,170230021,DE,,,,,,,,,170230021,1,Product used for unknown indication
17023013,170230132,2,F,201911,20191210,20191112,20191211,EXP,,US-GILEAD-2019-0437025,GILEAD,,55,YR,A,M,Y,77.8,KG,20191211,,PH,US,US,SUSTIVA,Depressed level of consciousness;Gastrointestinal tube insertion;Hypotension;Pneumonia aspiration;Respiratory failure;Rhabdomyolysis,170230132,HO,,,,,,,,,170230132,1,Product used for unknown indication
17029149,170291491,1,I,,20191031,20191114,20191114,EXP,,NG-AUROBINDO-AUR-APL-2019-071385,AUROBINDO,,,,,,Y,,,20191114,,OT,NG,NG,EFAVIRENZ.,Confusional state;Oedema;Somnolence,170291491,OT,,,,,,,,,170291491,1,Product used for unknown indication
17029920,170299201,1,I,,20191031,20191114,20191114,EXP,,NG-AUROBINDO-AUR-APL-2019-071383,AUROBINDO,,,,,,Y,,,20191114,,OT,NG,NG,EFAVIRENZ.,Confusional state;Hyperkinesia;Somnolence;Stridor,170299201,OT,,,,,,,,,170299201,1,Product used for unknown indication
17034605,170346051,1,I,,20191112,20191115,20191115,EXP,,CA-009507513-1911CAN004586,MERCK,,52,YR,,M,Y,,,20191115,,OT,CA,CA,SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,170346051,CA,,,,,,,,,170346051,1,HIV infection
17040024,170400241,1,I,,20191113,20191116,20191116,EXP,,GB-GILEAD-2019-0437798,GILEAD,,,,A,M,Y,,,20191116,,MD,GB,GB,EFAVIRENZ.,Body mass index increased;Diabetes mellitus;Glomerular filtration rate decreased;Hypertension;Proteinuria,170400241,OT,,,,,,,,,170400241,1,HIV infection
17041530,170415301,1,I,201310,20191111,20191118,20191118,EXP,,GB-TEVA-2019-GB-1138447,TEVA,"NIKOLOUSIS E. GRAFT-VERSUS-LEUKAEMIA EFFECT POST FLUDARABINE, MELPHALAN AND ALEMTUZUMAB REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTAT IN HIV-INFECTED PATIENT WITH ACUTE MYELOID LEUKAEMIA. BONE-MARROW-TRANSPLANT.",39,YR,,M,Y,,,20191118,,OT,GB,GB,EFAVIRENZ.,Acute myeloid leukaemia,170415301,OT,,,170415301,1,200308,200311,,,170415301,1,B precursor type acute leukaemia
17042336,170423361,1,I,,20191112,20191118,20191118,EXP,,CA-009507513-1911CAN004576,MERCK,,44,YR,,M,Y,,,20191118,,OT,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,170423361,HO,,,,,,,,,170423361,1,HIV infection
17046127,170461271,1,I,,20190214,20191119,20191119,EXP,,CA-AUROBINDO-AUR-APL-2019-010734,AUROBINDO,,45,YR,,M,Y,,,20191119,,CN,CA,CA,EFAVIRENZ.,Multiple-drug resistance,170461271,OT,,,,,,,,,170461271,1,HIV infection
17048421,170484211,1,I,20070313,20191112,20191119,20191119,EXP,US-EMA-20170412-KUMARNVEVHP-112118607,US-GILEAD-2019-0437138,GILEAD,,45,YR,A,M,Y,100,KG,20191119,,MD,US,US,EFAVIRENZ.,Aplasia pure red cell;Axillary vein thrombosis;Febrile neutropenia;Squamous cell carcinoma;Subclavian vein thrombosis;Venous thrombosis,170484211,OT,,,170484211,1,20060628,20070412,,,170484211,1,HIV infection
17048850,170488501,1,I,,20191112,20191119,20191119,EXP,,US-GILEAD-2019-0437421,GILEAD,,62,YR,A,M,Y,,,20191119,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Laboratory test abnormal;Poisoning,170488501,OT,,,,,,,,,170488501,1,Product used for unknown indication
17051507,170515071,1,I,,20191108,20191120,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-073468,AUROBINDO,,54,YR,,M,Y,,,20191120,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,170515071,OT,,,,,,,,,170515071,1,HIV infection
17052970,170529701,1,I,20191022,,20191022,20191022,DIR,,,FDA-CTU,,59,YR,,M,N,,,20191022,N,,US,US,SUSTIVA,Product use issue;Viral load abnormal,,,,,170529701,1,201910,201910,,,170529701,1,HIV infection
17055866,170558661,1,I,,20191111,20191120,20191120,EXP,,GB-AUROBINDO-AUR-APL-2019-073748,AUROBINDO,,70,YR,,M,Y,,,20191121,,MD,GB,GB,Efavirenz Film-coated Tablet,Neurotoxicity,170558661,OT,,,,,,,,,170558661,1,HIV infection
17056191,170561911,1,I,,20191112,20191121,20191121,EXP,,CA-009507513-1911CAN004547,MERCK,,54,YR,,M,Y,,,20191121,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,170561911,DE,,,,,,,,,170561911,1,HIV infection
17069235,170692352,2,F,,20191111,20191125,20191126,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-108547,BRISTOL MYERS SQUIBB,,70,YR,,M,Y,,,20191126,,MD,GB,GB,EFAVIRENZ.,Neurotoxicity,170692352,OT,,,,,,,,,170692352,1,HIV infection
17070306,170703061,1,I,,20191118,20191125,20191125,EXP,,BR-STRIDES ARCOLAB LIMITED-2019SP011710,STRIDES,,30,YR,,F,Y,,,20191125,,OT,BR,BR,EFAVIRENZ.;TENOFOVIR DISOPROXIL FUMARATE/LAMIVUDINE/EFAV (EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE),Maternal exposure during pregnancy;Premature delivery,170703061,OT,,,,,,,,,170703061,1,Product used for unknown indication
17070307,170703071,1,I,,20191118,20191125,20191125,EXP,,GB-STRIDES ARCOLAB LIMITED-2019SP011715,STRIDES,,39,YR,,F,Y,,,20191125,,OT,GB,GB,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,170703071,OT,,,,,,,,,170703071,1,Product used for unknown indication
17070318,170703181,1,I,,20191118,20191125,20191125,EXP,,GB-STRIDES ARCOLAB LIMITED-2019SP011717,STRIDES,,,,,,Y,,,20191125,,OT,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Premature baby,170703181,OT,,,,,,,,,170703181,1,Product used for unknown indication
17070326,170703261,1,I,,20191118,20191125,20191125,EXP,,BR-STRIDES ARCOLAB LIMITED-2019SP011711,STRIDES,,,,,F,Y,,,20191125,,OT,BR,BR,EFAVIRENZ.;TENOFOVIR DISOPROXIL FUMARATE/LAMIVUDINE/EFAV (EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE),Foetal exposure during pregnancy;Low birth weight baby;Premature baby,170703261,OT,,,,,,,,,170703261,1,Product used for unknown indication
17071591,170715911,1,I,,20191118,20191125,20191125,EXP,,UG-MYLANLABS-2019M1112753,MYLAN,,33,YR,,F,Y,,,20191125,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Maternal exposure during pregnancy;Stillbirth,170715911,OT,,,,,,,,,170715911,1,Product used for unknown indication
17075948,170759481,1,I,,20191121,20191126,20191126,EXP,,GR-GILEAD-2019-0439495,GILEAD,,,,A,,Y,,,20191126,,MD,GR,GR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug abuse;Drug ineffective,170759481,OT,,,,,,,,,170759481,1,Hepatitis C
17079970,170799701,1,I,,20191112,20191127,20191127,EXP,,CH-VIIV HEALTHCARE LIMITED-CH2019GSK212262,VIIV,"WAGNER N, WYLER-LAZAREVIC CA, YERLY S, SAMER C, PEYTAVIN G, POSFAY-BARBE KM ET AL. DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY IN A SEVERELY OVERWEIGHT CHILD WITH A MULTIDRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS INFECTION. A CASE REPORT AND REVIEW.. NEW MICROBES NEW INFECT. 2015;6:DOI.10.1016/J.NMNI.2015.02.003",,,C,M,Y,,,20191127,,OT,CH,CH,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,170799701,OT,,,,,,,,,170799701,1,HIV infection
17079974,170799741,1,I,,20191112,20191127,20191127,EXP,,CH-GLAXOSMITHKLINE-CH2019GSK212262,GLAXOSMITHKLINE,"WAGNER N, WYLER-LAZAREVIC CA, YERLY S, SAMER C, PEYTAVIN G, POSFAY-BARBE KM ET AL. DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY IN A SEVERELY OVERWEIGHT CHILD WITH A MULTIDRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS INFECTION. A CASE REPORT AND REVIEW.. NEW MICROBES NEW INFECT. 2015;6:DOI.10.1016/J.NMNI.2015.02.003",,,C,M,Y,,,20191127,,OT,CH,CH,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,170799741,OT,,,,,,,,,170799741,1,HIV infection
17084668,170846681,1,I,20181001,20190716,20191127,20191127,EXP,,"BW-LANNETT COMPANY, INC.-BW-2019LAN001043",LANNETT,,0,DY,,,Y,,,20191127,,OT,BW,BW,EFAVIRENZ.,Anencephaly;Foetal exposure during pregnancy;Meningomyelocele;Spina bifida;Stillbirth,170846681,OT,,,,,,,,,170846681,1,Product used for unknown indication
17084680,170846801,1,I,,20191118,20191127,20191127,EXP,,"CA-LANNETT COMPANY, INC.-CA-2019LAN001186",LANNETT,,,,,,Y,,,20191127,,OT,CA,CA,EFAVIRENZ/EMTRICITABIN/TENOFOVIRDISOPROXIL MY,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,170846801,OT,,,,,,,,,170846801,1,Product used for unknown indication
17086665,170866651,1,I,,20180604,20191128,20191128,EXP,,CA-APOTEX-2018AP015491,APOTEX,,,,,,Y,,,20191128,,CN,CA,CA,EMTRICITABINE/TENOFOVIR DISOPROXIL/EFAVIRENZ (EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE),Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,170866651,CA,,,,,,,,,170866651,1,Prophylaxis against HIV infection
17087202,170872021,1,I,,20191118,20191128,20191128,EXP,,GB-AUROBINDO-AUR-APL-2019-075486,AUROBINDO,,,,A,M,Y,,,20191128,,MD,GB,GB,EFAVIRENZ.,Body mass index increased;Diabetes mellitus;Glomerular filtration rate decreased;Hypertension;Proteinuria,170872021,OT,,,,,,,,,170872021,1,HIV infection
17093344,170933441,1,I,,20191125,20191129,20191129,EXP,,ZA-GILEAD-2019-0439767,GILEAD,"MORARE NMT, ROSE DM, APPELS O. OESOPHAGEAL TUBERCULOSIS WITH CONCOMITANT CANDIDIASIS: A RARE CAUSE OF DYSPHAGIA.. BMJ CASE REPORTS. 2019;12:UNK. DOI:10.1136/BCR-2019-231435",23,YR,A,F,Y,,,20191129,,OT,ZA,ZA,EFAVIRENZ.,Immune reconstitution inflammatory syndrome associated tuberculosis,170933441,OT,,,,,,,,,170933441,1,HIV infection
17094025,170940251,1,I,,20191115,20191129,20191129,EXP,,US-GLAXOSMITHKLINE-UG2019GSK213561,GLAXOSMITHKLINE,"PASTICK KA, NALINTYA E, TUGUME L, SSEBAMBULIDDE K, STEPHENS N, EVANS EE ET AL.. CRYPTOCOCCOSIS IN PREGNANCY AND THE POSTPARTUM PERIOD: CASE SERIES AND SYSTEMATIC REVIEW WITH RECOMMENDATIONS FOR MANAGEMENT. MEDICAL MYCOLOGY. 2019;1-11, DOI: 10.1093/MMY/MYZ084",27,YR,,F,Y,,,20191129,,OT,US,UG,EFAVIRENZ.,Ectopic pregnancy;Exposure during pregnancy,170940251,OT,,,,,,,,,170940251,1,Prophylaxis
17094026,170940261,1,I,,20191115,20191129,20191129,EXP,,US-VIIV HEALTHCARE LIMITED-UG2019GSK213561,VIIV,"PASTICK KA, NALINTYA E, TUGUME L, SSEBAMBULIDDE K, STEPHENS N, EVANS EE ET AL.. CRYPTOCOCCOSIS IN PREGNANCY AND THE POSTPARTUM PERIOD: CASE SERIES AND SYSTEMATIC REVIEW WITH RECOMMENDATIONS FOR MANAGEMENT. MEDICAL MYCOLOGY. 2019;1-11, DOI: 10.1093/MMY/MYZ084",27,YR,,F,Y,,,20191129,,OT,US,UG,EFAVIRENZ.,Ectopic pregnancy;Exposure during pregnancy,170940261,OT,,,,,,,,,170940261,1,Prophylaxis
17094054,170940541,1,I,20180208,20191118,20191129,20191129,EXP,,BR-MYLANLABS-2019M1116091,MYLAN,,0,DY,,F,Y,3.63,KG,20191129,,OT,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Congenital skin dimples;Foetal exposure during pregnancy;Transient tachypnoea of the newborn;Umbilical hernia,170940541,LT,,,,,,,,,170940541,1,Product used for unknown indication
17094109,170941091,1,I,,20191115,20191129,20191129,EXP,,US-GLAXOSMITHKLINE-UG2019GSK213564,GLAXOSMITHKLINE,"PASTICK KA, NALINTYA E, TUGUME L, SSEBAMBULIDDE K, STEPHENS N, EVANS EE ET AL.. CRYPTOCOCCOSIS IN PREGNANCY AND THE POSTPARTUM PERIOD: CASE SERIES AND SYSTEMATIC REVIEW WITH RECOMMENDATIONS FOR MANAGEMENT. MEDICAL MYCOLOGY. 2019;1-11, DOI: 10.1093/MMY/MYZ084",23,YR,,F,Y,,,20191129,,OT,US,UG,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,170941091,OT,,,,,,,,,170941091,1,HIV infection
17094110,170941101,1,I,,20191115,20191129,20191129,EXP,,US-VIIV HEALTHCARE LIMITED-UG2019GSK213564,VIIV,"PASTICK KA, NALINTYA E, TUGUME L, SSEBAMBULIDDE K, STEPHENS N, EVANS EE ET AL.. CRYPTOCOCCOSIS IN PREGNANCY AND THE POSTPARTUM PERIOD: CASE SERIES AND SYSTEMATIC REVIEW WITH RECOMMENDATIONS FOR MANAGEMENT. MEDICAL MYCOLOGY. 2019;1-11, DOI: 10.1093/MMY/MYZ084",23,YR,,F,Y,,,20191129,,OT,US,UG,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,170941101,OT,,,,,,,,,170941101,1,HIV infection
17094111,170941111,1,I,,20191115,20191129,20191129,EXP,,US-VIIV HEALTHCARE LIMITED-UG2019GSK216637,VIIV,"PASTICK KA, NALINTYA E, TUGUME L, SSEBAMBULIDDE K, STEPHENS N, EVANS EE ET AL.. CRYPTOCOCCOSIS IN PREGNANCY AND THE POSTPARTUM PERIOD: CASE SERIES AND SYSTEMATIC REVIEW WITH RECOMMENDATIONS FOR MANAGEMENT. MEDICAL MYCOLOGY. 2019;1-11, DOI: 10.1093/MMY/MYZ084",,,,,Y,,,20191129,,OT,US,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Stillbirth,170941111,DE,,,,,,,,,170941111,1,HIV infection
17094112,170941121,1,I,,20191115,20191129,20191129,EXP,,US-GLAXOSMITHKLINE-UG2019GSK216637,GLAXOSMITHKLINE,"PASTICK KA, NALINTYA E, TUGUME L, SSEBAMBULIDDE K, STEPHENS N, EVANS EE ET AL.. CRYPTOCOCCOSIS IN PREGNANCY AND THE POSTPARTUM PERIOD: CASE SERIES AND SYSTEMATIC REVIEW WITH RECOMMENDATIONS FOR MANAGEMENT. MEDICAL MYCOLOGY. 2019;1-11, DOI: 10.1093/MMY/MYZ084",,,,,Y,,,20191129,,OT,US,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Stillbirth,170941121,OT,,,,,,,,,170941121,1,HIV infection
17096196,170961961,1,I,,20191118,20191202,20191202,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-111396,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20191202,,MD,GB,GB,EFAVIRENZ.,Body mass index increased;Diabetes mellitus;Glomerular filtration rate decreased;Hypertension;Proteinuria,170961961,OT,,,,,,,,,170961961,1,HIV infection
17111075,171110751,1,I,20191101,20191202,20191204,20191204,EXP,,US-GILEAD-2019-0440898,GILEAD,,42,YR,A,M,Y,,,20191204,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diarrhoea;Pneumonia;Product use issue;Pyrexia,171110751,OT,,,171110751,1,200912,,,,171110751,1,HIV infection
17113099,171130991,1,I,20191114,20191203,20191204,20191204,EXP,ES-AEMPS-568082,ES-GILEAD-2019-0440732,GILEAD,,43,YR,A,M,Y,,,20191204,,PH,ES,ES,EFAVIRENZ SANDOZ,Erythema;Rash,171130991,OT,,,171130991,1,20170801,20191114,,,171130991,1,HIV test positive
17114731,171147311,1,I,,20191202,20191205,20191205,EXP,,GB-GILEAD-2019-0440913,GILEAD,,43,YR,A,F,Y,,,20191205,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,171147311,OT,,,,,,,,,171147311,1,Product used for unknown indication
17124376,171243761,1,I,,20191202,20191206,20191206,EXP,,IT-MYLANLABS-2019M1119580,MYLAN,"CASTAGNA A, MUCCINI C, GALLI L, BIGOLONI A, POLI A, SPAGNUOLO V, ET AL.. ANALYTICAL TREATMENT INTERRUPTION IN CHRONIC HIV-1 INFECTION: TIME AND MAGNITUDE OF VIRAL REBOUND IN ADULTS WITH 10 YEARS OF UNDETECTABLE VIRAL LOAD AND LOW HIV-DNA (APACHE STUDY). J. ANTIMICROB. CHEMOTHER.. 2019;74(7):2039-46",,,A,,Y,,,20191206,,OT,IT,IT,EFAVIRENZ.,Blood HIV RNA increased,171243761,OT,,,,,,,,,171243761,1,HIV infection
17125266,171252661,1,I,,20191125,20191207,20191207,EXP,,GB-AUROBINDO-AUR-APL-2019-103281,AUROBINDO,,,,,,Y,,,20191207,,CN,GB,GB,Efavirenz Film-coated Tablet,Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,171252661,OT,,,171252661,2,20171006,,,,171252661,1,Product used for unknown indication
17127310,171273101,1,I,20171006,20180828,20191209,20191209,EXP,GB-EMA-DD-20180827-KSEVHUMANWT-125137,GB-EMCURE PHARMACEUTICALS LTD-2018-EPL-0506,EMCURE,,,,,M,Y,,,20191209,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,171273101,CA,,,171273101,5,20171006,20180205,,,171273101,1,Product used for unknown indication
17129467,171294671,1,I,2012,20191202,20191209,20191209,EXP,,AT-MYLANLABS-2019M1119555,MYLAN,SCHALK H.. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS.2019. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019,,,,M,Y,,,20191209,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,171294671,OT,,,171294671,1,20040423,201708,,,171294671,1,Antiretroviral therapy
17135027,171350271,1,I,,20191128,20191210,20191210,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK223524,GLAXOSMITHKLINE,"DONG W, GUI H, FENG Y. STUDY ON MATERNAL INFECTION AND PREGNANCY OUTCOME OF PREGNANCY WITH HIV INFECTION. CHINESE MEDICAL RECORD. 2019;20:98-101",,,N,,Y,2.4,KG,20191210,,OT,CN,CN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission;Low birth weight baby,171350271,OT,,,,,,,,,171350271,1,HIV infection
17135031,171350311,1,I,,20191128,20191210,20191210,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK224172,GLAXOSMITHKLINE,"DONG W, GUI H, FENG Y. STUDY ON MATERNAL INFECTION AND PREGNANCY OUTCOME OF PREGNANCY WITH HIV INFECTION. CHINESE MEDICAL RECORD. 2019;20:98-101",,,N,,Y,,,20191210,,OT,CN,CN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,171350311,OT,,,,,,,,,171350311,1,HIV infection
17135041,171350411,1,I,,20191128,20191210,20191210,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK223524,VIIV,"DONG W, GUI H, FENG Y. STUDY ON MATERNAL INFECTION AND PREGNANCY OUTCOME OF PREGNANCY WITH HIV INFECTION. CHINESE MEDICAL RECORD. 2019;20:98-101",,,N,,Y,2.4,KG,20191210,,OT,CN,CN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission;Low birth weight baby,171350411,OT,,,,,,,,,171350411,1,HIV infection
17135044,171350441,1,I,,20191128,20191210,20191210,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK224172,VIIV,"DONG W, GUI H, FENG Y. STUDY ON MATERNAL INFECTION AND PREGNANCY OUTCOME OF PREGNANCY WITH HIV INFECTION. CHINESE MEDICAL RECORD. 2019;20:98-101",,,N,,Y,,,20191210,,OT,CN,CN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,171350441,OT,,,,,,,,,171350441,1,HIV infection
17136745,171367451,1,I,,20191206,20191210,20191210,EXP,,FR-MYLANLABS-2019M1122263,MYLAN,,,,,,Y,,,20191210,,CN,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Osteopenia;Osteoporosis,171367451,OT,,,,,,,,,171367451,1,Product used for unknown indication
17140455,171404551,1,I,,20191129,20191211,20191211,EXP,,LV-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-115856,BRISTOL MYERS SQUIBB,,70,YR,,M,Y,,,20191211,,MD,LV,LV,EFAVIRENZ.,Acute myocardial infarction;Cardiac disorder;Coronary artery disease,171404551,OT,,,171404551,1,201501,,,,171404551,1,HIV infection
17142409,171424091,1,I,20181226,20191203,20191211,20191211,EXP,,BY-JNJFOC-20191205757,JOHNSON AND JOHNSON,,43,YR,,M,Y,71,KG,20191211,,MD,BY,BY,EFAVIRENZ.,Cataract;Death;Gastric disorder;Hepatic failure;Hepatitis toxic;Nephropathy toxic,171424091,LT,,,171424091,1,20180814,20190129,,,171424091,1,Tuberculosis
17148237,171482371,1,I,201310,20191129,20191212,20191212,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-118294,BRISTOL MYERS SQUIBB,,39,YR,,M,Y,,,20191212,,CN,GB,GB,EFAVIRENZ.,Acute myeloid leukaemia;Product use in unapproved indication,171482371,HO,,,171482371,5,200308,,,,171482371,1,Bone marrow conditioning regimen
17149957,171499571,1,I,20171006,20191129,20191213,20191213,EXP,,GB-IPCA LABORATORIES LIMITED-IPC-2019-GB-002161,IPCA,,,,,,Y,,,20191213,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,171499571,OT,,,171499571,4,20171006,20180205,,,171499571,1,Product used for unknown indication
17150366,171503661,1,I,20190216,20191014,20191213,20191213,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019APC185465,VIIV,,,,,,Y,,,20191213,,MD,CN,CN,EFAVIRENZ TABLET,Pulmonary tuberculosis,171503661,DE,,,171503661,1,20180821,20190105,,,171503661,1,HIV test positive
17150391,171503911,1,I,20190216,20191014,20191213,20191213,EXP,,CN-GLAXOSMITHKLINE-CN2019APC185465,GLAXOSMITHKLINE,,,,,,Y,,,20191213,,MD,CN,CN,EFAVIRENZ TABLET,Pulmonary tuberculosis,171503911,DE,,,171503911,1,20180821,20190105,,,171503911,1,HIV test positive
17160832,171608321,1,I,20171101,20191211,20191216,20191216,EXP,,ZA-GILEAD-2019-0442396,GILEAD,,25,YR,A,F,Y,,,20191216,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,171608321,OT,,,171608321,1,20170606,,,,171608321,1,HIV infection
17160877,171608771,1,I,20181203,20191211,20191216,20191216,EXP,,ZA-GILEAD-2019-0442840,GILEAD,,32,YR,A,F,Y,,,20191216,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,171608771,OT,,,171608771,1,20180315,,,,171608771,1,HIV infection
17163638,171636381,1,I,,20191216,20191217,20191217,EXP,,US-GILEAD-2019-0443063,GILEAD,,42,YR,A,M,Y,,,20191217,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pneumonia,171636381,HO,,,,,,,,,171636381,1,HIV infection
17163716,171637161,1,I,2018,20191213,20191217,20191217,EXP,,US-GILEAD-2019-0442894,GILEAD,,65,YR,E,M,Y,,,20191217,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Prostate cancer,171637161,HO,,,,,,,,,171637161,1,HIV infection
17165297,171652971,1,I,20170813,20191211,20191217,20191217,EXP,,ZA-GILEAD-2019-0442856,GILEAD,,43,YR,A,F,Y,,,20191217,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,171652971,OT,,,171652971,1,20170330,,,,171652971,1,HIV infection
17165320,171653201,1,I,20170501,20191211,20191217,20191217,EXP,,ZA-GILEAD-2019-0442388,GILEAD,,30,YR,A,F,Y,,,20191217,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,171653201,OT,,,171653201,1,20170224,,,,171653201,1,HIV infection
17165324,171653241,1,I,20190506,20191212,20191217,20191217,EXP,,ZA-GILEAD-2019-0442860,GILEAD,,35,YR,A,F,Y,,,20191217,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,171653241,OT,,,171653241,1,20180117,,,,171653241,1,HIV infection
17166275,171662751,1,I,,20191210,20191217,20191217,EXP,,ES-MYLANLABS-2019M1123320,MYLAN,"RUIZ-ALGUERO M, SUAREZ-GARCIA I, ALVAREZ-DEL ARCO D, LAZARO P, MORENO S, JARRIN I.. USE OF HEALTH RESOURCES AND COSTS ASSOCIATED TO FIRST-LINE ANTIRETROVIRAL THERAPY IN THE ERA OF INTEGRASE INHIBITORS.. PHARMACEUTICAL CARE ESPANA.. 2019;21:86-109",,,A,,Y,,,20191217,,MD,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,171662751,OT,,,,,,,,,171662751,1,HIV infection
17167670,171676701,1,I,,20190603,20191218,20191218,EXP,,CO-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-210749,RANBAXY,,38,YR,,M,Y,,,20191218,,OT,CO,CO,EFAVIRENZ.,Drug ineffective;Herpes simplex;Toxic skin eruption,171676701,OT,,,,,,,,,171676701,1,Genital herpes
17168394,171683941,1,I,20191101,,20191125,20191125,DIR,,,FDA-CTU,,58,YR,,M,N,,,20191125,N,,US,US,SUSTIVA,Insomnia;Nightmare;Therapy cessation,,,,,171683941,1,201901,201911,,,171683941,1,HIV infection
17178834,171788341,1,I,,20191212,20191219,20191219,EXP,,CA-ROCHE-2499425,ROCHE,,54,YR,,M,Y,,,20191219,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,171788341,OT,,,,,,,,,171788341,1,HIV infection
17180948,171809481,1,I,,20191206,20191220,20191220,EXP,,GB-AUROBINDO-AUR-APL-2019-105719,AUROBINDO,,43,YR,,F,Y,,,20191220,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,171809481,OT,,,,,,,,,171809481,1,Product used for unknown indication
17187134,171871341,1,I,,20191216,20191220,20191220,EXP,,JP-GILEAD-2019-0443510,GILEAD,"HORIUCHI H, SAWAKI K, SASAKI H, MIYATA N, YOSHIMURA Y, TACHIKAWA N, TSUDA A, YANAGI H. O07-030 ONE CASE OF A PATIENT WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) POSSIBLY DEVELOPED REFRACTORY ABSCESS FROM THE ILIOPSOAS MUSCLE TO THE THIGH BY TUBERCULOSIS IMMUNE RECONSTITUTION SYNDROME. THE 33RD ANNUAL MEETING OF THE JAPANESE SOCIETY OF AIDS RESEARCH. 2019;21(4):416",37,YR,A,M,Y,,,20191220,,MD,JP,JP,EFAVIRENZ.,Immune reconstitution inflammatory syndrome associated tuberculosis,171871341,OT,,,,,,,,,171871341,1,HIV test positive
17187844,171878441,1,I,201310,20191207,20191221,20191221,EXP,,GB-AUROBINDO-AUR-APL-2019-105955,AUROBINDO,,39,YR,,M,Y,,,20191221,,OT,GB,GB,EFAVIRENZ.,Acute myeloid leukaemia;Product use in unapproved indication,171878441,HO,,,171878441,4,200308,200311,,,171878441,1,HIV infection CDC category C
17198087,171980871,1,I,,20191213,20191225,20191225,EXP,,CA-ROCHE-2500389,ROCHE,,54,YR,,M,Y,,,20191225,,OT,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,171980871,OT,,,,,,,,,171980871,1,Bipolar disorder
17198283,171982831,1,I,,20191216,20191225,20191225,EXP,,CA-ROCHE-2501805,ROCHE,,54,YR,,M,Y,,,20191225,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,171982831,OT,,,,,,,,,171982831,1,Product used for unknown indication
17198302,171983021,1,I,,20191217,20191225,20191225,EXP,,CA-ROCHE-2503023,ROCHE,,54,YR,,M,Y,,,20191225,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,171983021,OT,,,,,,,,,171983021,1,Bipolar disorder
17200843,172008431,1,I,,20191212,20191226,20191226,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2019-08531,LUPIN,,42,YR,,M,Y,,,20191226,,OT,DE,DE,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,172008431,OT,,,,,,,,,172008431,1,HIV infection
17200846,172008461,1,I,,20191212,20191226,20191226,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2019-08529,LUPIN,,7,YR,,M,Y,,,20191226,,OT,DE,DE,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,172008461,OT,,,,,,,,,172008461,1,HIV infection
17200991,172009911,1,I,,20191219,20191226,20191226,EXP,,CA-ROCHE-2504996,ROCHE,,54,YR,,M,Y,,,20191226,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,172009911,OT,,,,,,,,,172009911,1,Bipolar disorder
17200997,172009971,1,I,,20191216,20191226,20191226,EXP,,CA-ROCHE-2501974,ROCHE,,,,,M,Y,,,20191226,,OT,CA,CA,EFAVIRENZ.,Depression;Drug interaction,172009971,OT,,,,,,,,,172009971,1,Product used for unknown indication
17201006,172010061,1,I,,20191217,20191226,20191226,EXP,,CA-ROCHE-2502535,ROCHE,,54,YR,,M,Y,,,20191226,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,172010061,OT,,,,,,,,,172010061,1,Bipolar disorder
17202563,172025631,1,I,20110825,20191217,20191226,20191226,EXP,,FR-MYLANLABS-2019M1126225,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL.. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM. BIOL. DRUG DES.. 2018",35,YR,,F,Y,,,20191226,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,172025631,OT,,,,,,,,,172025631,1,HIV infection
17205220,172052201,1,I,,20171205,20191227,20191227,EXP,,CA-AUROBINDO-AUR-APL-2019-094941,AUROBINDO,,,,,M,Y,,,20191227,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,172052201,OT,,,,,,,,,172052201,1,Product used for unknown indication
17205315,172053151,1,I,,20191118,20191227,20191227,PER,,US-STRIDES ARCOLAB LIMITED-2019SP011725,STRIDES,,31,YR,,F,Y,,,20191227,,OT,US,US,EFAVIRENZ.,Maternal exposure during pregnancy;No adverse event,,,,,,,,,,,172053151,1,Product used for unknown indication
17205321,172053211,1,I,,20191118,20191227,20191227,PER,,US-STRIDES ARCOLAB LIMITED-2019SP011735,STRIDES,,34,YR,,F,Y,,,20191227,,OT,US,US,EFAVIRENZ.,Maternal exposure during pregnancy;No adverse event,,,,,,,,,,,172053211,1,Product used for unknown indication
17206727,172067271,1,I,,20160921,20191227,20191227,EXP,,CA-AUROBINDO-AUR-APL-2019-096562,AUROBINDO,,,,,M,Y,,,20191227,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,172067271,OT,,,,,,,,,172067271,1,Product used for unknown indication
17210299,172102991,1,I,,20191218,20191227,20191227,EXP,,CA-ROCHE-2504654,ROCHE,,54,YR,,M,Y,,,20191227,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,172102991,OT,,,,,,,,,172102991,1,Product used for unknown indication
17210318,172103181,1,I,,20191220,20191227,20191227,EXP,,CA-MYLANLABS-2019M1129617,MYLAN,,54,YR,,F,Y,46.2,KG,20191227,,PH,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE;TEVA EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Confusional state;Dizziness;Nightmare;Product substitution issue,172103181,OT,,,,,,,,,172103181,1,Product used for unknown indication
17214260,172142601,1,I,1996,20191218,20191230,20191230,EXP,,ES-MYLANLABS-2019M1127115,MYLAN,,38,YR,,M,Y,,,20191230,,OT,CL,ES,EFAVIRENZ.,Asthenia;Bone metabolism disorder;Bone pain;Chronic kidney disease;Drug abuse;Dyslipidaemia;Fanconi syndrome acquired;Fatigue;Glycosuria;Hypophosphataemia;Intentional product misuse;Lipodystrophy acquired;Medication error;Musculoskeletal pain;Myalgia;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,172142601,OT,,,172142601,1,2002,2011,,,172142601,1,Antiretroviral therapy
17216356,172163561,1,I,,20180511,20191230,20191230,EXP,IE-EMA-DD-20180509-RAKHIEVHPDD-164448,IE-GALDERMA-IE19077200,GALDERMA,"HEALTH AUTHORITY, BRODERICK C. BRODERICK C, QUINLAN C, GULMANN C, OKANE M. RECALCITRANT CUTANEOUS SARCOIDOSIS, WITH RESPONSE TO DAYLIGHT PHOTODYNAMIC THERAPY. J AM ACAD DERMATOL. 2017;76:AB216.. J AM ACAD DERMATOL.. 2017;.",37,YR,,F,Y,,,20191230,,OT,IE,IE,EFAVIRENZ.,Cushingoid;Drug ineffective for unapproved indication;Leukopenia;Product use in unapproved indication;Skin atrophy,172163561,OT,,,,,,,,,172163561,1,Sarcoidosis
17217518,172175181,1,I,201807,20190826,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-058844,AUROBINDO,"TSENG AL, ET,AL. DOLUTEGRAVIR/EFAVIRENZ/VALPROIC ACID INTERACTION SUBTHERAPEUTIC DRUG CONCENTRATION: CASE REPORT. REACTIONS WEEKLY. 2019;1767:P124",43,YR,,F,Y,,,20191231,,OT,CA,CA,EFAVIRENZ.,Anticonvulsant drug level below therapeutic;Antiviral drug level below therapeutic;Drug interaction;Seizure,172175181,OT,,,172175181,1,2016,,,,172175181,1,HIV infection
17220136,172201361,1,I,200311,20191226,20191231,20191231,EXP,,FR-MYLANLABS-2019M1131962,MYLAN,,36,YR,,F,Y,82,KG,20191231,,CN,FR,FR,SUSTIVA,Abdominal pain;Chills;Diarrhoea;Eyelid oedema;Lip oedema;Pyrexia;Rash;Thrombocytopenia,172201361,OT,,,172201361,1,20051201,20051202,,,172201361,1,Pyrexia
17240641,172406411,1,I,20191007,,20191212,20191212,DIR,,,FDA-CTU,,63,YR,,M,N,,,20191129,N,OT,US,US,EFAVIRENZ 600MG MYLAN,Diarrhoea;Manufacturing issue,,,172406411,HP,172406411,1,20191003,,,,172406411,1,HIV infection
17243257,172432571,1,I,,,20191212,20191212,DIR,,,FDA-CTU,,,,,M,N,,,20191204,N,OT,US,US,EFAVIRENZ.,Acute kidney injury,172432571,HO,172432571,HP,172432571,1,201201,,,,172432571,1,HIV infection
6049025,604902518,18,F,20060216,20191105,20060519,20191115,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13375589,BRISTOL MYERS SQUIBB,,25,YR,,F,Y,56,KG,20191115,,CN,FR,FR,SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,604902518,HO,,,604902518,1,20050513,20050908,,,604902518,1,HIV infection
8260766,826076611,11,F,2006,20191105,20111123,20191121,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15921299,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20191121,,CN,FR,FR,SUSTIVA,Anencephaly;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,826076611,OT,,,826076611,1,20050513,20050908,,,826076611,1,Product used for unknown indication
